

Current as of July 2006

*VANDERBILT UNIVERSITY SCHOOL OF MEDICINE*

**CURRICULUM VITAE**

**NAME**

Charles William Stratton, IV, MD

**TITLES**

Associate Professor of Pathology and Medicine  
Director, Clinical Microbiology Laboratory

**DEPARTMENT**

Pathology

**HOME ADDRESS**

207 Kensington Park  
Nashville, TN, 37215

**OFFICE ADDRESS**

Director, Clinical Microbiology Laboratory  
Department of Pathology  
Vanderbilt University Medical Center  
Room 4525-TVC  
21st and Edgehill  
Nashville, Tennessee 37232

**TELEPHONE NUMBERS**

Home	615-383-1347
Home Fax	615-298-3908
Office	615-343-9144
Office (direct)	615-343-9063
Office Fax	615-343-8420
Cellular	615-579-3944

**E-MAIL ADDRESS**

Charles.Stratton@Vanderbilt.edu

**BIRTH**

March 8, 1945, Worcester, Massachusetts

## **EDUCATION**

BS from Bates College (1963-1967)

Lewiston, ME

M.D. from the University of Vermont College of Medicine (1967-1971)

Burlington, VT

## **TRAINING**

Intern in Medicine (7/1/1971-6/30/1972)

Medical Center Hospital of Vermont, Burlington, VT

Junior Resident in Medicine (7/1/1972-6/30/1973)

Medical Center Hospital of Vermont, Burlington, VT

Senior Resident in Medicine (7/1/1973-6/30/1974)

University of Colorado Medical Center, Denver, CO

Fellow in Infectious Diseases/Clinical Microbiology (7/1/1974-6/30/1976)

University of Colorado Medical Center, Denver, CO

## **BOARD CERTIFICATIONS**

DIPLOMATE: National Board of Medical Examiners

*Practice of Medicine* (1971)

DIPLOMATE: American Board of Internal Medicine

*Internal Medicine* (1974)

DIPLOMATE: American Board of Internal Medicine

*Infectious Diseases* (1976)

DIPLOMATE: The American Board of Pathology

*Medical Microbiology* (1978)

DIPLOMATE: The American Board of Medical Microbiology

*Public Health and Medical Microbiology* (1979)

## **ACADEMIC APPOINTMENTS**

Assistant Professor of Medicine (7/1/1976-6/30/1979)

West Virginia University Medical School

Charleston Division, Charleston, WV

Assistant Professor of Pathology (7/1/1979-6/30/1988)

Vanderbilt University School of Medicine

Nashville, TN

Assistant Professor of Medicine and Pathology (7/1/1979-6/30/1992)  
Vanderbilt University School of Medicine  
Nashville, TN

Associate Professor of Pathology (7/1/1988-Present)  
Vanderbilt University School of Medicine  
Nashville, TN

Associate Professor of Medicine (7/1/1992-Present)  
Vanderbilt University School of Medicine  
Nashville, TN

## **HOSPITAL APPOINTMENTS**

DIRECTOR: Clinical Microbiology Laboratory (7/1/1976-6/30/1979)  
Charleston Area Medical Center, Charleston, WV

DIRECTOR: Clinical Microbiology Laboratory (7/1/1979-Present)  
Vanderbilt University Medical Center, Nashville, TN

CONSULTANT: Pathology and Medicine (7/1/1979-6/30/1995)  
Veterans Administration Medical Center, Nashville, TN

## **PROFESSIONAL SOCIETIES**

FELLOW: American College of Physicians  
FELLOW: College of American Pathologists  
FELLOW: American Society of Clinical Pathologists  
FELLOW: American Academy of Microbiology  
FELLOW: Infectious Diseases Society of America  
MEMBER: Academy of Clinical Laboratory Physicians and Scientists  
MEMBER: American Society for Microbiology  
MEMBER: American Association for the Advancement of Science  
MEMBER: Sigma Xi Scientific Research Society

## **NATIONAL COMMITTEES**

MEMBER: Area Committee on Microbiology (1982-Present)  
National Committee for Clinical Laboratory Standards

CHAIRMAN: Subcommittee on the Serum Bactericidal Test (1982-Present)  
National Committee for Clinical Laboratory Standards

CHAIRMAN: Subcommittee on Bactericidal Testing Methods (1984-Present)  
National Committee for Clinical Laboratory Standards

MEMBER: Test Material Development (1986-1990)  
National Board of Medical Examiners

MEMBER: Council on Microbiology Committee for Education (1989-1995)  
American Society of Clinical Pathologists

## **EDITORIAL BOARD POSITIONS**

EDITOR: Bimonthly Section: *Topics in Clinical Microbiology* (1983-1997)  
Infection Control and Hospital Epidemiology

ASSOCIATE EDITOR (1984-1989) AND EDITOR (1989-1994)  
Infectious Diseases Newsletter

EDITOR: (1994-2002)  
Antimicrobics and Infectious Diseases Newsletter

MEMBER: Editorial Review Board (1982-1994; 2003-Present)  
The Journal of Clinical Microbiology

MEMBER: Editorial Review Board (1989-1994)  
Antimicrobial Agents and Chemotherapy

SECTION EDITOR: (1992-1993)  
American Society of Clinical Pathologists  
Microbiology Check Sample Series

## **CURRENT VANDERBILT COMMITTEES**

MEMBER: Environment and Infection Control Committee (1979-Present)  
Vanderbilt University Medical Center

DEPUTY CHAIRMAN: Environment and Infection Control Committee (1982-Present)  
Vanderbilt University Medical Center

MEMBER: Ethics Committee (1998-Present)  
Vanderbilt University Medical Center

MEMBER: Credentials Committee (1998-Present)  
Vanderbilt University Medical Center

CHAIRMAN: Culture Utilization Subcommittee (2000-Present)  
Vanderbilt University Medical Center

MEMBER: Institutional Biosafety Committee (2002-Present)  
Vanderbilt University

## **MILITARY ACTIVITIES**

United States Army National Guard (1971-1986)  
United States Army Reserve (1986-1990)  
Active Duty, United States Army (Persian Gulf War, 1990-1991)  
United States Army Reserve (1991-1998)

Rank and Status: Colonel-USAR (Retired)

Graduate: U.S. Army War College, Class of 1996 Correspondent Studies

Total Military Service: 33 years in Army National Guard/Army Reserve

Military Obligation: None

Military Awards

*Military Service:*

Bronze Star, Persian Gulf War  
Army Commendation Medal with two Oak Leaf Clusters  
Army Achievement Medal with one Oak Leaf Cluster

*Army Medical Department:*

"A" Proficiency Designator in Infectious Diseases

## **TEACHING ACTIVITIES**

LECTURER: Pathology 501 Course (1979-Present)

LECTURER: Grand Rounds in Pathology (1979-Present)

LECTURER: Grand Rounds in Medicine (1979-Present)

LECTURER: Grand Rounds in Infectious Diseases (1979-Present)

LECTURER: Clinical Management Course (1980-Present)

LECTURER: Medical Technologist Program (1981-Present)

ATTENDING: Infectious Diseases Service (1979-1998)  
Vanderbilt University Medical Center

ATTENDING: Infectious Diseases Service (1987-1998)  
Nashville Veterans Administration Hospital

DIRECTOR: Postgraduate Programs in Clinical Microbiology (1979-Present)  
1. Clinical Microbiology Portion: Pathology Residency Program.  
2. Clinical Microbiology Portion: Infectious Diseases Fellowship Program  
3. Clinical Microbiology Fellowship Program.

ASSOCIATE DIRECTOR: Pathology Residency Program (2005-Present)

## **INVITED NATIONAL/INTERNATIONAL ORAL PRESENTATIONS**

- 1978-79: Visiting Faculty, National Institutes of Health, Washington, District of Columbia  
*"Anaerobic Infections "*
- 1979-80: Visiting Faculty, University of Colorado School of Medicine, Denver, Colorado  
*"The Influence of Physician Education on the Utilization of the Microbiology Laboratory"*
- Visiting Faculty, University of Tennessee School of Medicine, Memphis, Tennessee  
*"Clinical Relevance and the Microbiology Laboratory "*
- Visiting Faculty, Louisiana State University School of Medicine, New Orleans, Louisiana  
*"Susceptibility Testing Revisited"*
- 1980-81: Visiting Faculty, Wright State University School of Medicine, Dayton, Ohio  
*"Blood Cultures"*
- Visiting Faculty, Indiana University School of Medicine, Indianapolis, Indiana  
*"Clinical Relevance and the Microbiology Laboratory"*
- 1981-82: Visiting Faculty, Oschner Clinic, New Orleans, Louisiana  
*"Update on Antibiotics"*
- Visiting Faculty, University of Missouri School of Medicine, Columbia, Missouri  
*"Susceptibility Testing Revisited"*
- 1982-83: Visiting Faculty, West Virginia University School of Medicine, Charleston, West Virginia  
*"Antibiotics in the '80s"*
- Visiting Faculty, Louisiana State University School of Medicine, New Orleans, Louisiana  
*"Aminoglycosides"*
- Visiting Faculty, Rutgers University School of Medicine, Piscataway, New Jersey  
*"Susceptibility Testing Revisited"*
- Visiting Faculty, Emory University School of Medicine, Atlanta, Georgia  
*"Clinical Relevance and the Microbiology Laboratory"*
- 1983-84: Visiting Faculty, University of Colorado School of Medicine, Denver, Colorado  
*"The Serum Bactericidal Test"*
- Visiting Faculty, Beth Israel Hospital, New York City, New York  
*"Susceptibility Testing Revisited"*

Visiting Faculty, Wilford Hall Air Force Hospital, San Antonio, Texas  
*"Endocarditis"*

Visiting Faculty, University of Mississippi School of Medicine, Jackson, Mississippi  
*"Cost Containment and the Treatment of Infections"*

Visiting Faculty, St. Jude's Hospital, Memphis, Tennessee  
*"AIDS"*

1984-85: Visiting Faculty, University of Louisville School of Medicine, Louisville, Kentucky  
*"Infections in the Elderly"*

Visiting Faculty, University of Georgia School of Medicine, Augusta, Georgia  
*"Update on Antibiotics"*

Visiting Faculty, University of Kansas School of Medicine, Wichita, Kansas  
*"Bacterial Pneumonia"*

Visiting Faculty, Louisiana State School of Medicine, Shreveport, Louisiana  
*"New Advances in Antimicrobial Action and Resistance"*

Visiting Faculty, Washington University School of Medicine, St. Louis, Missouri  
*"Choice of Antibiotics for the Treatment of Pneumonia"*

International Congress of Chemotherapy, Kyoto, Japan  
*"Standardization of the Serum Bactericidal Test and Its Relationship to Levels of Antimicrobial Agents"*

1985-86: Visiting Faculty, University of Maryland School of Medicine, Baltimore, Maryland  
*"Infection Control and DRGs"*

Southern Association for Clinical Microbiology Annual Meeting, Memphis, Tennessee  
*"Cost Containment in Clinical Microbiology"*

Visiting Faculty, University of Nebraska School of Medicine, Omaha, Nebraska  
*"Respiratory Infections in the Elderly"*

American Society of Clinical Pathology Workshop, San Antonio, Texas  
*"Clinical Aspects of Microbiology Interpretations and Decisions"*

British Cardiac Society/British Society for Antimicrobial Chemotherapy: Symposium on Endocarditis, London, England  
*"Endocarditis—Laboratory Monitoring of Therapy"*

Visiting Faculty, University of Wisconsin School of Medicine, Madison, Wisconsin  
*"New Concepts in Antimicrobial Activity and Bacterial Resistance"*

Visiting Faculty, University of Kentucky School of Pharmacy, Lexington, Kentucky  
*"Advances in Beta-lactamase-Mediated Resistance"*

- 1986-87: Visiting Faculty, University of Louisville School of Medicine, Louisville, Kentucky  
*"New Concepts in Antimicrobial Activity and Bacterial Resistance"*
- Visiting Faculty, Marshal University School of Medicine, Huntington, West Virginia  
*"Diagnosis and Treatment of Lower Respiratory Tract Infections"*
- Visiting Faculty, Oschner Clinic, New Orleans, LA  
*"Beta-lactamase Induction"*
- South Central Association for Clinical Microbiology, Columbus, Ohio  
*"Cost Effectiveness in the Microbiology Laboratory"*
- Visiting Faculty, Howard University School of Medicine, Washington, District of Columbia  
*"New Concepts in Beta-lactamase-Mediated Resistance"*
- 1987-88: Symposium on  $\beta$ -Lactamases: Questions and Controversies,  
27th Interscience Conference on Antimicrobial Agents and Chemotherapy, New York, New York  
*"Staphylococcal Beta-lactamase: Diversity and Role in Resistance"*
- Visiting Faculty, University of Alabama School of Medicine, Birmingham, Alabama  
*"New Concepts in Antimicrobial Activity and Bacterial Resistance"*
- Visiting Faculty, University of South Florida School of Medicine, Tampa, Florida  
*"The Role of Staphylococcal Beta-lactamase in Resistance"*
- Visiting Faculty, University of Minnesota School of Medicine, Minneapolis, Minnesota  
*"Current Concepts of Beta-lactamase Mediated Resistance"*
- Visiting Faculty, Medical College of Virginia, Richmond, Virginia  
*"Role of the Microbiology Laboratory in Formulary Decisions"*
- 1988-89: International Symposium on Basic Research and Clinical Aspects of *Pseudomonas aeruginosa*  
Infection, Copenhagen, Denmark  
*"Intrinsic Resistance of Pseudomonas aeruginosa"*
- Symposium on Susceptibility Testing, American Society for Microbiology, New York, New York  
*"Special Tests: Antimicrobial Assays and Serum Bactericidal Titers"*
- Workshop on Susceptibility Testing,  
28th Interscience Conference on Antimicrobial Agents and Chemotherapy, Los Angeles,  
California  
*"Susceptibility Testing Today: Myth, Reality, and New Direction"*
- Visiting Faculty, The Medical Center of Delaware, Wilmington, Delaware  
*"New Aspects of Staphylococcus aureus Beta-lactamase: A Clinical Problem"*
- Seminar: 89th Annual Meeting of the American Society for Microbiology, New Orleans,  
Louisiana  
*"Update on Antimicrobial Susceptibility Testing; Use and Abuse of Special Tests"*



- 1989-90: Visiting Faculty, Johns Hopkins University School of Medicine, Baltimore, Maryland  
*"Intrinsic Resistance of Pseudomonas aeruginosa"*
- Visiting Faculty, Robert Wood Johnson School of Medicine, New Brunswick, New Jersey  
*"New Insights on the Resistance Mechanisms of Staphylococci"*
- Visiting Faculty, U.S. Naval Medical Research Unit (NAMRU-3), Cairo, Egypt  
*"Time Kill-Kinetic Methodology as a Research Tool"*
- Visiting Faculty, The Medical College of Virginia, Richmond, Virginia  
*"New Insights on the Resistance Mechanisms of Staphylococci"*
- Visiting Faculty, University of Virginia School of Medicine, Charlottesville, Virginia  
*"New Insights on the Resistance Mechanisms of Staphylococci"*
- 1991-92: Visiting Faculty, Louisiana State University School of Medicine, New Orleans, Louisiana  
*"Operation Desert Storm: An Army Medical Odyssey"*
- Visiting Faculty, Institute Jules Bordet, Brussels, Belgium  
*"Emerging Trends in Gram-Negative Resistance: A New Concern for Critical Care Medicine"*
- Argentine Congress of Infectology, Buenos Aires, Argentina  
*"Bacterial Resistance to Quinolones"*
- 1992-93: Visiting Faculty, Vancouver Hospital, Vancouver, Canada  
*"Focused Microbiology Surveillance"*
- Visiting Faculty, Bethesda Naval Hospital, Washington, District of Columbia  
*"Anaerobic Infections"*
- Visiting Faculty, Emory Hospital, Atlanta, Georgia  
*"Update on Fluoroquinolones"*
- 1993-94: Visiting Faculty, Columbia University College of Physicians & Surgeons, New York, NY  
*"Mechanisms of Resistance for Staphylococcus aureus"*
- Visiting Faculty, Duke University School of Medicine, Durham, North Carolina  
*"New Insights on the Resistance Mechanisms of Staphylococci"*
- 1994-95: Visiting Faculty, University of South Alabama School of Medicine, Mobile, Alabama  
*"The Pneumococcus: Past, Present, and Future"*
- Visiting Faculty, Louisiana State University School of Medicine, New Orleans, Louisiana  
*"Penicillin- and Cephalosporin-Resistant Pneumococci"*
- International Congress on the Prevention and Treatment of Infectious Diseases,  
Buenos Aires, Argentina  
*"New Approaches to the Therapy of Mycobacterium tuberculosis Based upon Cell Physiology"*
- International Congress on the Prevention and Treatment of Infectious Diseases,  
Buenos Aires, Argentina  
*"The Pathogenesis of Helicobacter pylori"*

- 1995-96: Visiting Faculty, University of Kentucky School of Medicine. Lexington, Kentucky  
*"The Pathogenesis of Helicobacter pylori"*
- Special Forces Medical Conference, Fort Bragg, North Carolina  
*"Treating Life-Threatening Infections in the Field"*
- 1996-97: Third International Conference on Macrolides, Azalides, and Streptogramins, Lisbon, Portugal  
*"Macrolide Suppression of the Bacterial Glycocalyx of Pseudomonas aeruginosa"*
- 1997-98: Visiting Faculty, Duke University School of Medicine, Durham, North Carolina  
*"Pathogenesis of Chlamydial Infections"*
- 1998-99: Advances in Infectious Diseases. 25<sup>th</sup> Ludwig-Heilmeyer Symposium, Cologne, Germany  
*"Chlamydia pneumoniae Infection of the Central Nervous System in Patients with Progressive Multiple Sclerosis"*
- 9<sup>th</sup> European Congress of Clinical Microbiology and Infectious Diseases, Berlin, Germany  
*"Chlamydia pneumoniae and MS"*
- The Robert Koch Institut State-of-the-Art Conference on *Chlamydia pneumoniae* and chronic diseases. Berlin, Germany  
*"Association of Chlamydia pneumoniae with Multiple Sclerosis: Protocol for Detection of C. pneumoniae in the CSF and Summary of Preliminary Results"*
- Visiting Faculty, The Serum Stat Institut, Copenhagen, Denmark  
*"Strategies for Counteracting Resistance"*
- National Meeting of the Academy of Clinical Laboratory Physicians and Scientists. Birmingham, Alabama  
*"The Association of Chlamydia pneumoniae and Multiple Sclerosis"*
- 1999-00: International Conference on Advances in Therapeutics, University of Kuwait, Kuwait City, Kuwait  
*"The Therapy of Staphylococcal Infections"*
- 2000-01: 95<sup>th</sup> Annual Meeting of the Southern Medical Association. Orlando, Florida  
*"Options for the Treatment of Community-Acquired Respiratory Tract Infections"*
- 2001-02: Visiting Faculty, University of Iowa College of Medicine, Iowa City, Iowa  
*"Pathogenesis of Chlamydia Infections"*
- 96<sup>th</sup> Annual Meeting of the Southern Medical Association, Washington, DC  
*"Increasing Bacterial Resistance – An Update on the PROTEKT US Research"*
- 2002-03: Visiting Faculty, Meharry Medical College, Nashville, Tennessee  
*"Options for the Treatment of Respiratory Tract Infections"*
- Keynote Speaker, Pharmaceutical Business Intelligence & Research Group Annual General Meeting, Naples, Florida  
*"Interactions Between Physicians and the Pharmaceutical Industry: The Good, The Bad, and The Ugly"*

2004-05: Visiting Faculty, University of Tennessee School of Medicine, Memphis, Tennessee  
“*Bioterrorism: The Role of the Clinical Microbiology Laboratory*”

### ***LABORATORY RESEARCH PUBLICATIONS***

1. *Stratton, C.W., Reller, L.B.*: Serum dilution test for bactericidal activity. I. Selection of a physiologic diluent. *J. Infect. Dis.* 136:187-195, 1977.
2. *Reller, L.B., Stratton, C.W.*: Serum dilution test for bactericidal activity. II. Standardization and correlation with antimicrobial assays and susceptibility tests. *J. Infect. Dis.* 136:196-204, 1977.
3. *McKee, K.T., Wright, P.F., Gregg, C.R., Stratton, C.W.*: Initial evaluation of kinetics and efficacy of moxalactam (LY 127935) in neonatal systemic gram-negative bacterial disease. *Current Ther. Research* 28:603-610, 1980.
4. *Tu, K.K., Jorgensen, J.H., Stratton, C.W.*: A rapid paper-disc test for penicillinase. *Am. J. Clin. Path.* 75:557-559, 1981.
5. *Reimer, L.G., Stratton, C.W., Reller, L.B.*: Minimum inhibitory and bactericidal concentrations of 44 antimicrobials for three standard control strains in broth with and without human serum. *Antimicrob. Agents Chemother.* 19:1050-1055, 1981.
6. *Stratton, C.W., Weinstein, M.P., Reller, L.B.*: Correlation of serum bactericidal activity with antimicrobial agent level and minimal bactericidal concentration. *J. Infect. Dis.* 145:160-168, 1982.
7. *Evans, M.E., Patterson, L.S., Stratton, C.W.*: *In vitro* comparison of clindamycin and pirlimycin (U-57930E) activity against *Staphylococcus aureus*. *Antimicrob. Agents Chemother.* 22:334-335, 1982.
8. *Aldridge, K.E., Stratton, C.W., Patterson, L.S., Evans, M.E., Hodges, R.L.*: Comparison of the API Staph-Ident System with a conventional method for speciation of urine and blood isolates of coagulase-negative staphylococci. *J. Clin. Microbiol.* 17:516-520, 1983.
9. *Ratner, H.B., Tinsley, H.T., Keller, R.E., Stratton, C.W.*: Comparison of the effect of refrigerated versus room temperature media on the isolation of *Neisseria gonorrhoeae* from genital specimens. *J. Clin. Microbiol.* 21:127-128, 1985.
10. *Weinstein, M.P., Stratton, C.W., Ackley, A.M., Hawley, H.B., Robinson, P.A., Fisher, B.D., Alcid, D.V., Stevens, D.S., Reller, L.B.*: Multicenter collaborative evaluation of a standardized serum bactericidal test as a prognostic indicator in infective endocarditis. *Am. J. Med.* 78:262-269, 1985.

11. Ratner, H.B., Stratton, C.W.: Thermonuclease test for same day identification of *Staphylococcus aureus* from blood cultures. J. Clin. Microbiol. 21:995-996, 1985.
12. Tausk, F., Evans, M.E., Patterson, L.S., Federspiel, C.F., Stratton, C.W.: Imipenem induced resistance to antipseudomonal beta-lactams in *Pseudomonas aeruginosa*. Antimicrob. Agents Chemother. 28:41-45, 1985.
13. Stratton, C.W., Evans, M.E., Hawley, H.B., Horsman, T.A., Tu, K.K., Reller, L.B.: Effect of human serum on inhibition of growth of *Staphylococcus aureus* by antimicrobial agents. Eur. J. Clin. Microbiol. 5:351-354, 1986.
14. Weinstein, M.P., Reller, L.B., Mirrett, S., Stratton, C.W., Reimer, L.G., Wang, W.L.: Controlled evaluation of the agar-slide and radiometric blood culture systems for the detection of bacteremia and fungemia. J. Clin. Microbiol. 23:221-225, 1986.
15. Ratner, H.B., Weeks, L.S., Stratton, C.W.: Evaluation of the spot CAMP test for the identification of Group B Streptococci. J. Clin. Microbiol. 24:296-297, 1986.
16. Tausk, F., Stratton, C.W.: Effect of clavulanic acid on the activity of ticarcillin against *Pseudomonas aeruginosa*. Antimicrob. Agents Chemother. 30:584-589, 1986.
17. Stratton, C.W., Evans, M.E., Hawley, H.B., Horsman, T.A., Tu, K.K., Reller, L.B.: Effect of human serum on inhibition of growth of *Staphylococcus aureus* by antimicrobial agents. Eur. J. Clin. Microbiol. 5:351-354, 1986.
18. May, D.G., Stratton, C.W., Denney, W.D., Watts, F.L., Bernard, G.R., Branch, R.A.: Vancomycin entry into lung lymph in sheep. Antimicrob. Agents Chemother. 31:1689-1691, 1987.
19. Stratton, C.W., Weeks, L.S., Tausk, F.: Beta-lactamase induction and aminoglycoside susceptibility in *Pseudomonas aeruginosa*. J. Antimicrob. Chemother. 19:21-25, 1987.
20. Tausk, F., Stratton, C.W.: Beta-lactamase alteration of beta-lactam inhibition zones. Eur. J. Clin. Microbiol. 6:474-476, 1987.
21. Stratton, C.W., Weeks, L.S., Aldridge, K.: Comparison of a time-kill curve method with agar and broth dilution methods for the determination of antimicrobial activity for selected agents against members of *Bacteroides fragilis* group. J. Clin. Microbiol. 25:645-649, 1987.
22. Stratton, C.W., Liu, C., Ratner, H.B., Weeks, L.S.: Bactericidal activity of deptomycin compared with ciprofloxacin, vancomycin, ampicillin, and gentamicin against enterococci as determined by kill-kinetic studies. Antimicrob. Agents Chemother. 31:1014-1016, 1987.

23. Stratton, C.W., Liu, C., Weeks, L.S.: Bactericidal activity of debrinomicin compared with methicillin, cefazolin, cefamandole, cefuroxime, ciprofloxacin, and vancomycin against staphylococci as determined by kill-kinetic studies. *Antimicrob. Agents Chemother.* 31:1210-1215, 1987.
24. Weinstein, M.P., Stratton, C.W., Hawley, H.B., Ackley, A., Reller, L.B.: Multicenter collaborative evaluation of a standardized serum bactericidal test as a predictor of the therapeutic efficacy in acute and chronic osteomyelitis. *Am. J. Med.* 83:218-222, 1987.
25. Weinstein, M.P., Reller, L.B., Mirret, S., Reimer, L.G., Wang, W.L., Stratton, C.W.: Controlled evaluation of a modified radiometric blood culture medium supplemented with gelatin for the detection of bacteremia and fungemia. *J. Clin. Microbiol.* 25:1373-1375, 1987.
26. Stratton, C.W., Weinstein, M.P., Mirret, S., Paisley, J., Lauer, B.A., Reller, L.B.: Controlled evaluation of blood culture medium containing gelatin and V-factor analog for the detection of septicemia in children. *J. Clin. Microbiol.* 26:747-749, 1988.
27. Evans, M.E., Schaffner, W., Federspiel, C.F., Cotton, R.B., McKee, K.T., Stratton, C.W.: Sensitivity, specificity and predictive value of surface cultures in neonatal intensive care unit. *J. Am. Med. Assoc.* 259:248-252, 1988.
28. Weinstein, M.P., Reller, L.B., Mirrett S., Stratton, C.W., Paisley, J.W., Lauer, B.A.: Controlled evaluation of radiometric tryptic soy broth versus radiometric tryptic soy broth with 10% sucrose for the detection of bacteremia and fungemia in pediatric patients. *J. Clin. Microbiol.* 27:2448-2450, 1989.
29. Kernodle, D.S., Stratton, C.W., Williams, L.J., Chipley, J.R., McGraw, P.A.: Beta-lactamase variants of *Staphylococcus aureus*: differentiation by substrate hydrolysis profiles. *J. Infect. Dis.* 159:103-108, 1989.
30. Stratton, C.W., Kernodle, D.S., Eades, S.C., Weeks, L.S.: Evaluation of cefotaxime alone and in combination with desacetylcefotaxime against strains of *Staphylococcus aureus* which produce variants of staphylococcal beta-lactamase. *Diagn. Microbiol. Infect. Dis.* 12: 57-65, 1989.
31. Stratton, C.W., Franke, J.J., Weeks, L.S., Manion, F.A.: Comparison of the bactericidal activity of ciprofloxacin alone and in combination with selected antipseudomonal beta-lactam agents against clinical isolates of *Pseudomonas aeruginosa*. *Diagn. Microbiol. Infect. Dis.* 11:41-52, 1989.
32. Aldridge, K.E., Weeks, L.S., Stratton, C.W., Sanders, C.V.: Comparison of the bactericidal activity of cefotaxime and desacetylcefotaxime alone and in combination against strains of the *Bacteroides fragilis* group organisms. *Diagn. Microbiol. Infect. Dis.* 12:165-170, 1989.

33. Stratton, C.W., Weeks, L.S.: Bactericidal activity of lomefloxacin (NY-198) and ciprofloxacin against selected pathogens. *Diagn. Microbiol. Infect. Dis.* 12(Supp. 3):S29-S34, 1989.
34. Kernodle, D.S., McGraw, P.A., Stratton, C.W., Kaiser, A.B.: Use of extracts versus whole-cell bacterial suspensions in the identification of *Staphylococcus aureus* beta-lactamase variants. *Antimicrob. Agents Chemother.* 34:420-425, 1990.
35. Stratton, C.W., Gelfand, M.S., Gerberding, J.L., Chambers, H.F.: Characterization of mechanisms of resistance to beta-lactam antibiotics in methicillin-resistant strains of *Staphylococcus saprophyticus*. *Antimicrob. Agents Chemother.* 34:1780-1781, 1990.
36. Aldridge, K.E., Weeks, L.S., Stratton, C.W., Sanders, C.V.: Differences in the *in vitro* inhibitory and bactericidal activity of ceftizoxime, cefoxitin, cefotetan, and penicillin G against *Bacteroides fragilis* group isolates: comparison of time-kill kinetic studies with MIC values. *Diagn. Microbiol. Infect. Dis.* 13:311-316, 1990.
37. Stratton, C.W., Weeks, L.S.: Effect of human serum on the bactericidal activity of daptomycin and vancomycin against staphylococci and enterococci isolates as determined by time-kill kinetic studies. *Diagn. Microbiol. Infect. Dis.* 13:245-252, 1990.
38. Weinstein, M.P., Mirrett, S., Wilson, M.L., Harrell, L.J., Stratton, C.W., Reller, L.B.: Controlled evaluation of the BACTEC PLUS 26 and ROCHE SEPTI-CHEK aerobic blood culture bottles. *J. Clin. Microbiol.* 29:878-879, 1991.
39. Appleman, M.D., Cherubin, C.E., Heseltine, P.N.R., Stratton, C.W.: Susceptibility testing of *Listeria monocytogenes*: a reassessment of bactericidal activity as a predictor for clinical outcome. *Diagn. Microbiol. Infect. Dis.* 14:311-317, 1991.
40. Stratton, C.W., Weeks, L.S., Aldridge, K.E.: Comparison of the bactericidal activity of metronidazole and clindamycin against cefoxitin-susceptible and cefoxitin-resistant isolates of the *Bacteroides fragilis* group. *Diagn. Microbiol. Infect. Dis.* 14:377-382, 1991.
41. Aldridge, K.E., Stratton, C.W.: Bactericidal activity of ceftizoxime, cefotetan, and clindamycin against cefoxitin-resistant *Bacteroides fragilis* group strains. *J. Antimicrob. Chemother.* 28:701-705, 1991.
42. Stratton, C.W., Weeks, L.S., Aldridge, K.E.: Inhibitory and bactericidal activity of selected beta-lactam agents alone and in combination with beta-lactamase inhibitors compared with that of cefoxitin and metronidazole against cefoxitin-susceptible and cefoxitin-resistant isolates of the *Bacteroides fragilis* group. *Diagn. Microbiol. Infect. Dis.* 15:321-330, 1992.
43. Wilson, M.L., Harrell, L.J., Mirrett, S., Weinstein, M.P., Stratton, C.W., Reller, L.B.: Controlled evaluation of BACTEC PLUS 27 and ROCHE SEPTI-CHEK anaerobic blood culture bottles. *J. Clin. Microbiol.* 30:63-66, 1992.

44. Zygmunt, D.J., Stratton, C.W., Kernodle, D.S.: Characterization of four beta-lactamases produced by *Staphylococcus aureus*. Antimicrob. Agents Chemother. 36:440-445, 1992.
45. Archer, G.L., Auger, P., Doern, G.V., Ferraro, M.J., Fuchs, P.C., Jorgensen, J.H., Low, D.E., Murray, P., Reller, L.B., Stratton, C.W., Wennersten, C., Moellering, Jr., R.C.: RP 59500 is highly active against recent isolates of North American staphylococci. Diagn. Microbiol. Infect. Dis. 16:223-226, 1993.
- 46 Norris, S.R., Stratton, C.W., Kernodle, D.S.: Production of A and C variants of staphylococcal beta-lactamase by methicillin-resistant strains of *Staphylococcus aureus*. Antimicrob. Agents Chemother. 38:1649-1650, 1994.
47. Cherubin, C.E., Stratton, C.W.: An assessment of the bactericidal activity of sparfloxacin, ofloxacin, levofloxacin, and other fluoroquinolones in comparison with selected agents of proven efficacy against *Listeria monocytogenes*. Diagn. Microbiol. Infect. Dis. 20:21-25, 1994.
48. Hass, D.W., Stratton, C.W., Griffin, J.P., Weeks, L., Allis, S.: Diminished activity of ceftizoxime in comparison to cefotaxime and ceftriaxone against *Streptococcus pneumoniae*. Clin. Infect. Dis. 20:671-677, 1995.
49. Stratton, C.W., Aldridge, K.E., Gelfand, M.S.: In vitro killing of penicillin-susceptible, -intermediate, and -resistant strains of *Streptococcus pneumoniae* by cefotaxime, ceftriaxone, and ceftizoxime: A comparison of bactericidal and inhibitory activity with achievable CSF levels. Diagn. Microbiol. Infect. Dis. 22:35-42, 1995.
50. Coudron, P.E., Stratton, C.W.: Utilization of time-kill kinetic methodologies for assessing the bactericidal activities of ampicillin and bismuth, alone and in combination, against *Helicobacter pylori* in stationary and logarithmic growth phases. Antimicrob. Agents Chemother. 39:66-69, 1995.
51. Hyatt, J.M., Nix, D.E., Stratton, C.W., Schentag, J.J.: In vitro pharmacodynamics of piperacillin, piperacillin-tazobactam, and ciprofloxacin alone and in combination against *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Enterobacter cloacae*, and *Pseudomonas aeruginosa*. Antimicrob. Agents Chemother. 39:1711-1716, 1995.
52. Coudron, P.E., Stratton, C.W.: Factors affecting growth and susceptibility testing of *Helicobacter pylori* in liquid media. J. Clin. Microbiol. 33:1028-1030, 1995.
53. Coudron, P.E., Stratton, C.W.: Use of time-kill methodology to assess antimicrobial combinations against metronidazole-susceptible and metronidazole-resistant strains of *Helicobacter pylori*. Antimicrob. Agents Chemother. 39:2641-2644, 1995.
54. Brandt, C.M., Rouse, M.S., Laue, N.W., Stratton, C.W., Wilson, W.R., Steckelberg, J.M.: Effective treatment of multidrug-resistant enterococcal experimental endocarditis with combinations of cell-wall active agents. J. Infect. Dis. 173:909-913, 1996.

55. Kernodle, D.S., Classen, D.C., Stratton, C.W., Kaiser, A.B.: Association of borderline oxacillin-susceptible strains of *Staphylococcus aureus* with surgical wound infections. J. Clin. Microbiol. 36:219–222, 1998.
56. Coudron, P.E., Stratton, C.W.: The bactericidal activity of clarithromycin versus ampicillin alone and in combination with omeprazole and/or bismuth against clarithromycin-susceptible and clarithromycin-resistant strains of *Helicobacter pylori*. Diagn. Microbiol. Infect. Dis. 31:39–44, 1998.
57. Coudron, P.E., Stratton, C.W.: *In-vitro* evaluation of nitrofurantoin as an alternative agent for metronidazole in combination antimicrobial therapy against *Helicobacter pylori*. J. Antimicrob. Chemother. 42:657–660, 1998.
58. Stratton, C.W., Warner, R.R., Coudron, P.E., Lilly, N.A.: Bismuth-mediated disruption of the glycocalyx-cell wall of *Helicobacter pylori*: ultrastructure evidence for a mechanism of action for bismuth salts. J. Antimicrob. Chemother. 43:659–666, 1999.
59. Sriram, S., Stratton, C.W., Yao, S., Tharp, A., Ding, L., Bannan, J.D., Mitchell, W.M.: *Chlamydia pneumoniae* infection of the CNS in multiple sclerosis. Ann. Neurol. 46:6–14, 1999.
60. Stratton, C.W., Sriram, S., Yao, S., Tharp, A., Ding, L., Bannan, J.D., Mitchell, W.M.: *Chlamydia pneumoniae* Infection of the central nervous system in patients with progressive multiple sclerosis. pp 204–211. In : New Advances in Infectious Diseases. Proceedings of the 25<sup>th</sup> Symposium of the Society for Progress in Internal Medicine. Lode, H., Siegenthaler, W. (Eds.), Georg Thieme Publishers, Stuttgart, New York, 1999.
61. Hernanz-Schulman, M., Foster, C., Maxa, R., Battles, G., Dutt, P., Stratton, C., Holburn, G., Schulman, G., Neblett, W.W., Shyr, Y., Hakim, R.R., Vanholder, R., Heller, R.M. Experimental study of mortality and morbidity of contrast media and standardized fecal dose in the peritoneal cavity. Ped. Radiol. 30:396–378, 2000.
62. Yao, S.-Y., Rose, A., Stratton, C.W., Mitchell, W.M., Sriram, S.: Regulation by beta interferon of inducible nitric oxide synthase and interleukin 12/p40 in murine macrophages exposed to *Chlamydia pneumoniae* antigens. J Interferon Cytokine Res, 21:137–146, 2001.
63. Yao, S., Stratton, C.W., Mitchell, W.M., Sriram, S.: CSF oligoclonal bands in multiple sclerosis include antibodies against *Chlamydia*. Neurol., 56:1168–1176, 2001.
64. Sriram, S., Yao, S., Stratton, C.W., Calabresi, P., Mitchell, W.M., Ikejima, I., Yamamoto, Y.: Comparative study of the presence of *Chlamydia pneumoniae* in cerebrospinal fluid of patients with clinical definite and monosymptomatic multiple sclerosis. Clin. Diagn. Lab. Immunol., 9:1332–1337, 2002.
65. Tang, Y.W., Li, H., Durkin, M.M, Sefers, S.E., Meng, S., Connolly, P.A., Stratton, C.W., Wheat, L.J. Urine polymerase chain reaction is not as sensitive as urine antigen for the diagnosis of disseminated histoplasmosis. Diagn. Microbiol. Infect. Dis. 2006.



## ***CLINICAL AND EPIDEMIOLOGICAL PUBLICATIONS***

1. *Stratton, C.W., Phelps, D., Reller L.B.: Tuberculoid tenosynovitis and carpal tunnel syndrome caused by Mycobacterium szulgai. Am. J. Med. 65:349-351, 1978.*
2. *Weinstein, M., Iannini, P.B., Stratton, C.W., Eickhoff, T.C.: Spontaneous bacterial peritonitis in cirrhosis: epidemiologic and prognostic factors. Am. J. Med. 64: 592-598, 1978.*
3. *Horsman, T.A., Zekan, W.J., Stratton, C.W., Hawley, H.B.: An outbreak of shigellosis in Kanawha County, West Virginia. W. Va. Med. J. 76:103-108, 1980.*
4. *Stratton, C.W., Hawley, H.B., Horsman, T.A., Tu, K.K., Ackley, A., Fernando, N.K., Weinstein, M.: Hemophilus influenzae pneumonia in adults. Report of five cases caused by ampicillin-resistant strains. Am. Rev. Resp. Dis. 121:595-598, 1980.*
5. *Stratton, C.W., Lichtenstein, K.A., Lowenstein, S.R., Phelps, D.B., Reller, L.B.: Granulomatous tenosynovitis and carpal tunnel syndrome caused by Sporothrix schenckii. Am. J. Med. 71:161-164, 1981.*
6. *Torres-Rojas, J.R., Stratton, C.W., Sanders, C.V., Horsman, T.A., Hawley, H.B., Dascomb, H.E., Vial, L.J.: Candidal suppurative peripheral thrombophlebitis. Ann. Intern. Med. 96:431-435, 1982.*
7. *McKee, K.T., Cotton, R.B., Stratton, C.W., Lavelly, G.B., Wright, P.F. Shenai, J.P., Evans, M.E., Melly, M.A., Farmer, J.J., Karzon, D.T., Schaffner, W.: Nursery epidemic due to multiply-resistant Klebsiella pneumoniae: epidemiologic setting and impact on perinatal health care delivery. Infect. Control 3:150-156, 1982.*
8. *Gregory, D.W., Blackburn, W.D., Madhavan, S.V., Manske, C.L., Stratton, C.W.: Esophageal candidiasis: treatment with ketoconazole. Southern Med. J. 76:1307-1308, 1983.*
9. *Gustafson, T.L., Schaffner, W., Lavelly, G.B., Stratton, C.W., Johnson, H.K., Hutcheson, Jr., R.H.: Invasive aspergillosis in renal transplant recipients: correlation with corticosteroid therapy. J. Infect. Dis. 148:230-238, 1983.*
10. *Mitchell, R.T., Marshall, L.H., Lefkowitz, L.B., Stratton, C.W.: Falsely elevated serum creatinine levels secondary to the presence of 5-fluorocytosine. Am. J. Clin. Path. 84:251-253, 1985.*
11. *DeLozier, III, J.B., Stratton, C.W., Potts, III, J.R.: Rapid diagnosis of Candida sepsis in surgical patients. Am. Surgeon 53:600-602, 1987.*

12. Cherubin, C.E., Appleman, M.D., Heseltine, P.N.R., Kahyr, W., *Stratton, C.W.*: Epidemiologic spectrum and current therapy of listeriosis. *Rev. Infect. Dis.* 13:1108-1114, 1991.
13. *Stratton, C.W.*, Ratner, H., Johnston, P.E., Schaffner, W.: Focused microbiological surveillance by specific hospital unit as a sensitive means of defining unit-specific problems. *Diagn. Microbiol. Infect. Dis.* 15(Suppl. 2):S11-S18, 1992.
14. Pappas, P.G., Pottage, J.C., Powderly, W.G., Fraser, V.J., *Stratton, C.W.*, McKenzie, S., Tapper, M.L., Chmel, H., Bonebrake, F.C., Blum, R., Shafer, R.W., King, C., Dismukes, W.E.: Blastomycosis in patients with the acquired immunodeficiency syndrome. *Ann. Intern. Med.* 116:847-853, 1992.
15. Macon, W.R., Lo, S.C., Poiesz, B.J., Montefiori, D.C., Mason, T.E., Michael, P.R., Cohen, A.G., Davis, C.M., Cousar, J.B., *Stratton, C.W.*: Aids-like illness associated with *Mycoplasma fermentans* (incognitus strain) infection in an HIV-negative homosexual male. *Human Pathol.* 24:554-557, 1993.
16. *Stratton, C.W.*, Ratner, H., Johnston, P.E., Schaffner, W.: Focused microbiologic surveillance by specific hospital unit: practical application and clinical utility. *Clin. Ther.* 15(Suppl A):S12-S20, 1993.
17. *Stratton, C.W.*: Efficacy and safety of cefixime for the empiric therapy of acute bronchitis and AECB. *Infections in Med.* 10(Suppl. B):S11-S15, 1993.
18. Peterson, W.L., Graham, D.Y., Marshall, B., Blaser, M.J., Genta, R.M., Klein, P.D., *Stratton, C.W.*, Drnec, J., Prokocimer, P., Siepmann, N.: Clarithromycin as monotherapy for eradication of *Helicobacter pylori*: a randomized, double-blind trial. *Am. J. Med.* 88:1860-1864, 1993.
19. Antony, S.J., Matherin, P., *Stratton, C.W.*: Increased bactericidal activity as documented by serum bactericidal titers for a triple combination of cell wall active agents against gentamicin resistant enterococci. *Scand. J. Infect. Dis.* 27:401-403, 1995.
20. Spearman, P., Lakey, D., Jotte, S., Chernowitz, A., Claycolmb, S., *Stratton, C.W.*: Sternoclavicular joint septic arthritis with small-colony variant *Staphylococcus aureus*. *Diagn. Microbiol. Infect. Dis.* 26:13-15, 1996.
21. Antony, S.J., *Stratton, C.W.*, Dummer, J.S.: *Lactobacillus* bacteremia: description of the clinical characteristics in adult patients without endocarditis. *Clin. Infect. Dis.* 23:773-778, 1996.
22. Antony, S.J., Ladner, J., *Stratton, C.W.*, Raudales, F., Dummer, S.J.: High-level aminoglycoside-resistant enterococcus causing endocarditis successfully treated with a combination of ampicillin, imipenem and vancomycin. *Scand. J. Infect. Dis.* 29: 628-630, 1997.
23. Sriram, S., Mitchell, W., *Stratton, C.*: Multiple sclerosis associated with *Chlamydia pneumoniae* infection of the CNS. *Neurol.* 50: 571-573, 1998.

24. Vannucci, S.A., Mitchell, W.M., *Stratton, C.W.*, King, L.E. Jr.: Pyoderma gangrenosum and *Chlamydia pneumoniae* infection in a diabetic man: pathogenic role or coincidence? J. Am. Acad. Dermatol., 42: 295-297, 2000.
25. King L.E. Jr., Bushman T., *Stratton C.W.*, Mitchell, W.M.: Diabetic foot ulcers and *Chlamydia pneumoniae*: innocent bystander or opportunistic pathogen? Arch. Dermatol., 137: 671-672, 2001.
26. Kirsche, D.L., Jones, T.F., *Stratton, C.W.*, Barnett, J.A., Schaffner, W.: Outbreak of joint and soft-tissue infections associated with injections from multiple-dose medication vials. Clin. Infect. Dis. 36:1369-1373, 2003.
27. Sams, H.H., Mitchell, W.M., *Stratton, C.W.*, King, L.E.: Culture and immunohistochemical evidence of *Chlamydia pneumoniae* in pyoderma gangrenosum. J. Am. Acad. Dermatol., 48:966-969, 2003.
28. Alberts, G.L., Mitchell, W.M., *Stratton, C.W.*, Franke, J.J.: Interstitial cystitis: can *Chlamydia pneumoniae* be a cause? Infect. Urol., 16: 19-21, 2003.
29. *Stratton, C.W.*, Brown, S.D.: Comparative *in vitro* activity of telithromycin and beta-lactam antimicrobials against community-acquired bacterial respiratory tract pathogens in the United States: findings from the PROTEK US Study, 2000-2001. Clin. Therapeutics 26:522-530, 2004.
30. Sriram, S., Yao, S.Y., *Stratton, C.W.*, Moses, H. Narayana, P.A., Wolinsky, J.S.: Pilot study to examine the effect of antibiotic therapy on MRI outcomes in RRMS. J. Neurol. Sci. 234:87-91, 2005.
31. Perz, J.F., Craig, A.S., *Stratton, C.W.*, Bodner, S.J., Phillips, W.E. Jr., Schaffner, W. *Pseudomonas putida* septicemia in a special care nursery due to contaminated flush solutions prepared in a hospital pharmacy. J. Clin. Microbiol. 43:5316-5318, 2005.
32. Muldrew, K.L., Simpson, J.F., *Stratton, C.W.*, Tang, Y.W. Molecular diagnosis of necrotizing fasciitis by 16S rRNA gene sequencing and superantigen gene detection. J. Mol. Diagn. 7:641-645, 2005.
33. Rankin, J.S., Glower, D.D., Teichmann, T.L., Muhlbaier, L.H., *Stratton, C.W.* Immunotherapy for refractory pulmonary infection after adult cardiac surgery: immune dysregulation syndrome. J. Heart Valve Dis. 14:783-791, 2005.
34. Kilic, A., Urwin, R., Li, H., Saracli, M.A., *Stratton, C.W.*, Tang, Y.W. Clonal spread of serogroup W135 meningococcal disease in Turkey. J. Clin. Microbiol. 44:222-224, 2006.

## **REVIEW PUBLICATIONS**

1. *Stratton, C.W.*: Infection related to intravenous infusion. Heart and Lung 11:123-135, 1982.

2. Stratton, C.W.: Bacterial pneumonia—an overview with emphasis on pathogenesis, diagnosis, and treatment. *Heart and Lung* 15:226-244, 1986.
3. Anthony, L., Stratton, C.W.: A review of ceftriaxone: a long-acting cephalosporin. *Am. J. Med. Sci.* 296:1-2, 1988.
4. Stratton, C.W.: Activity of beta-lactamase against beta-lactams. *J. Antimicrob. Chemother.* 22(Suppl. A):S23-S35, 1988.
5. Stratton, C.W.: The serum bactericidal test. *Rev. Microbiol.* 1:19-26, 1988.
6. Stratton, C.W.: Laboratory tests in infectious diseases. *Intern. Med.* 10:71-122, 1989.
7. Stratton, C.W.: Fluoroquinolone antibiotics: properties of the class and individual agents. *Clin. Therapeutics* 14:348-375, 1992.
8. Stratton, C.W.: Bactericidal testing. *Infect. Dis. Clin. North America.* 7:445-459, 1993.
9. Stratton, C.W.: Blood cultures and immunocompromised patients. *Clinics Lab. Med.* 14:31-49, 1994.
10. Midha, N.K., Stratton, C.W.: Laboratory test in critical care. *Critical Care Clin.* 14:15-34, 1998.
11. Stratton, C.W.: Pharmacokinetics, pharmacodynamics, and tolerability profile of clinafloxacin. *Clin. Drug Invest.* 15(Suppl. 1):19-34, 1998.
12. Stratton, C.W.: Role of *Chlamydia pneumoniae* in connective tissue diseases. *Antibiotics for Clinicians* 2(Suppl. 3):31-38, 1998.
13. Stratton, C.W.: Mechanisms of bacterial resistance to antimicrobial agents. *Lebanese Med. J.* 48:186-198, 2000.
14. Antony, S.J., Diaz-Vasquez, E., Stratton, C.W.: Clinical experience with linezolid in the treatment of resistant Gram-positive infections. *J. Nat. Med. Assoc.* 93:386-391, 2001.
15. Stratton, C.W.: Pharmacokinetic, pharmacodynamic and tolerability profiles of telithromycin, the first ketolide antimicrobial agent. *Today's Ther. Trends* 20:37-58, 2002.
17. Stratton, C.W.: Mechanisms and patterns of antibiotic resistance in respiratory pathogens. *J. Respir. Dis.* 23(Suppl.):S15-S23, 2002.
18. King, L.E., Jr., Stratton, C.W., Mitchell, W.M.: *Chlamydia pneumoniae* and chronic skin infections: a focused review. *J. Invest. Dermatol. Symp. Proc.* 6:233-237, 2002.

19. *Stratton, C.W.*: Dead bugs don't mutate: susceptibility issues in the emergence of bacterial resistance. *Emerg. Infect. Dis.* 9:10-16, 2003.

20. *Stratton, C.W.*: Antimicrobial resistance in respiratory tract pathogens. *Expert Rev. Anti-infect. Ther.* 2:641-647, 2004.

### ***MISCELLANEOUS PUBLICATIONS***

1. *Stratton, C.W.*: Hot Body, Cold Urine. (Letter to the Editor) *N. Engl. J. Med.* 296:886, 1977.

2. *Stratton, C.W.*: Staphylococcal pseudobacteremia. *Infect. Control* 2:251-252, 1981.

3. *Stratton, C.W.*: Clinical relevance and the identification of microbes. (Editorial) *Clin. Microbiol. Newsletter* 3:74-75, 1981.

4. *Stratton, C.W.*: Tracheotomy and endotracheal tube specimens. *Infect. Control* 2:162-164, 1981.

5. *Stratton, C.W.*: Coagulase-positive staphylococci. *Infect. Control* 3:79-81, 1982.

6. *Stratton, C.W.*: Monograph: Beta-Lactamases. Marion Scientific Company, St. Louis, Missouri, 1982.

7. *Stratton, C.W.*: *Pseudomonas aeruginosa*. *Infect. Control* 4:36-40, 1983.

8. *Stratton, C.W.*: The usefulness of the serum cidal test in orthopedic infections. *Orthopedics* 7:1579-1580, 1984.

9. *Stratton, C.W.*: Infections in the elderly. *Infect. Dis. Newsletter* 4:33-36, 1985.

10. Weinstein, M.P., *Stratton, C.W.*, Reller, L.B.: Current status of the serum bactericidal test as a monitor of therapeutic efficacy in serious infections. *Antimicrobics Newsletter* 3:9-14, 1986.

11. *Stratton, C.W.*: New strategies for the cost-effective use of antimicrobics. *Infect. Dis. Newsletter* 5:33-37, 1986.

12. *Stratton, C.W.*: Waterless agents for disinfecting the hands. *Infect. Control* 3:186-187, 1986.

13. *Stratton, C.W.*: Bacterial pneumonia: effect of risk factors and new pathogens on drug choice. *Consultant*, 115-126, March 1986.

14. *Stratton, C.W.*: Role of the microbiology laboratory in the cost-effective use of antibiotics. *Infect. Dis. Newsletter* 5:49-52, 1986.

15. *Stratton, C.W.*: Standardization of the serum bactericidal test and its relationship to levels of antimicrobial agents. (Editorial) *Eur. J. Clin. Microbiol.* 5:61-66, 1986.
16. *Stratton, C.W.*: The pathogenesis of AIDS. *Infect. Dis. Newsletter* 6:9-11, 1987.
17. *Stratton, C.W.*: New insights on the pathogenesis of rickettsial infections. *Infect. Dis. Newsletter* 6:75-78, 1987.
18. *Stratton, C.W.*: The role of the microbiology laboratory in the treatment of infective endocarditis. *J. Antimicrob. Chemother.* 20(Suppl. A):S41-S49, 1987.
19. *Stratton, C.W., Tausk, F.*: Synergistic resistance mechanisms in *Pseudomonas aeruginosa*. *J. Antimicrob. Chemother.* 19:413-416, 1987.
20. *Stratton, C.W.*: Common infections of the eye. *Infect. Dis. Newsletter* 7:33-35, 1988.
21. *Weinstein, M.P., Stratton, C.W., Reller, L.B.*: Use of the serum bactericidal test as a predictor of outcome in osteomyelitis. *Infect. Dis. Newsletter* 2:9-11, 1988.
22. *Stratton, C.W.*: Susceptibility testing today: myth, reality, and new direction. *Infect. Control Hosp. Epidemiol.* 9:264-267, 1988.
23. *Stratton, C.W.*: The problem of selecting antimicrobial agents before (or without) the results of susceptibility testing. *Infect. Control Hosp. Epidemiol.* 9:559-561, 1988.
24. *Stratton, C.W.*: New insights on the genetic basis for resistance. *Infect. Control Hosp. Epidemiol.* 10:371-375, 1989.
25. *Stratton, C.W.*: New insights into the diagnosis of AIDS. *Infect. Dis. Newsletter* 8:28-30, 1989.
26. *Stratton, C.W.*: A newly recognized epidemic: IV-associated phlebitis related to insertional trauma. *Infect. Dis. Newsletter* 8:11-12, 1989.
27. *Stratton, C.W.*: *Clostridium difficile* colitis in the hospital setting: a potentially explosive problem. (Editorial) *Infect. Control Hosp. Epidemiol.* 11:286, 1990.
28. *Stratton, C.W.*: Antifungal agents: the old and the new. *Infect. Dis. Newsletter* 9:41-45, 1990.
29. *Stratton, C.W.*: Comments on the optimal use of aminoglycosides. *Infect. Dis. Newsletter* 9:9-11, 1990.
30. *Stratton, C.W.*: *Moraxella cattarrhalis*: a new name for a new (?) pathogen. *Infect. Dis. Newsletter* 9:4-6, 1990.

31. Stratton, C.W.: *Pseudomonas aeruginosa* revisited. Infect. Control Hosp. Epidemiol. 11:101-104, 1990.
32. Stratton, C.W.: Combating *Pseudomonas* resistance with multidrug therapy. J. Critical Illness 5:215-222, 1990.
33. Stratton, C.W.: New advances in the diagnosis and therapy of schistosomiasis. Infect. Dis. Newsletter 9:19-20, 1990.
34. Stratton, C.W.: The use and abuse of blood cultures. Infect. Dis. Newsletter 10:27-30, 1991.
35. Stratton, C.W.: The laboratory diagnosis of meningitis. Infect. Dis. Newsletter 10:12-13, 1991.
36. Stratton, C.W.: Clinical microbiology in the 1990s: emerging pathogens and the role of the fluoroquinolones. Infect. Dis. Newsletter 11:25-29, 1992.
37. Stratton, C.W.: Visceral leishmaniasis caused by *Leishmania tropica* in American military personnel deployed to Southwest Asia during Operation Desert Storm. Infect. Dis. Newsletter 11:9-12, 1992.
38. Stratton, C.W.: The resurgence of tuberculosis. Infect. Dis. Newsletter 11:73-76, 1992.
39. Stratton, C.W.: Mycobacterial infections other than tuberculosis in the AIDS era. Infect. Dis. Newsletter 11:89-94, 1992.
40. Branch, R.A., Johnston, P., Koestner, J., Bluhm, R., Stratton, C.W., Knight, J.: The formulary: an educational tool for clinical pharmacology. Clin. Pharm. Ther. 51:481-488, 1992.
41. Stratton, C.W.: Eulogy for Charles E. Cherubin. Clin. Infect. Dis. 17:925, 1993.
42. Stratton, C.W.: The role of *Candida* in surgical intensive care unit infections. Infect. Dis. Newsletter 12:9-12, 1993.
43. Stratton, C.W., Johnston, P.E., Haas, D.W.: Lack of correlation between the use of a specific fluoroquinolone and the emergence of fluoroquinolone-resistant isolates of *Pseudomonas aeruginosa*: A tale of two hospitals. Antimicrobics Infect. Dis. Newsletter 13:25-29, 1994.
44. Stratton, C.W. (Ed.), Quinn, J., Peterson, L., Patterson, J.E., Patterson, T.F., Staskin, D., Anderson, C., Bohlman, L., Drehobl, M., Karram, M.M., Smith, D.A., Roberts, J., Fowler, J., Parsons, C.L., Mulholland, S.G., Kriegeir, J.N., Schaeffer A.: Emerging resistance in uropathogens: Its impact on management of acute cystitis in women. Consensus Conference Proceedings, Postgraduate Medicine, Special Report, Oct. 31, 1994.
45. Stratton, C.W.: Mechanisms of activity and resistance for fluoroquinolones. Antimicrobics Infect. Dis. Newsletter 14:69-72, 1995.

46. Stratton, C.W.: Antimicrobial resistance and the use of oral antimicrobial agents in the nursing home. *Antimicrobics Infect. Dis. Newsletter* 14:80-82, 1995.
47. Stratton, C.W.: The expanding horizons of infection control. (Editorial) *Infect. Control Hosp. Epidemiol.* 16:192-193, 1995.
48. Stratton, C.W.: The role of beta-lactamases. *Antimicrobics Infect. Dis. Newsletter* 15:17-24, 1996.
49. Stratton, C.W.: Beta-lactamase-mediated resistance in Gram-negative bacilli. *Antimicrobics Infect. Dis. Newsletter* 15:29-32, 1996.
50. Stratton, C.W.: Staphylococcal beta-lactamases. *Antimicrobics Infect. Dis. Newsletter* 15:51-53, 1996.
51. Stratton, C.W.: The clinical implications of beta-lactamases. *Antimicrobics Infect. Dis. Newsletter* 15:67-71, 1996.
52. Stratton, C.W., Mitchell, W.M.: The pathogenesis of *Chlamydia* species. *Antimicrobics Infect. Dis. Newsletter* 15:83-88, 1996.
53. Stratton, C.W.: Issues for chlamydial susceptibility testing. *Antimicrobics Infect. Dis. Newsletter* 16:14-16, 1997.
54. Stratton, C.W., Mitchell, W.M.: The pathogenesis of systemic chlamydial infections: theoretical considerations of host cell energy depletion and its metabolic consequences. *Antimicrobics Infect. Dis. Newsletter* 16:33-40, 1997.
55. File, T.M., Bartlett, J.G., Cassell, G.H., Gaydos, C.A., Grayston, J.T., Hammerschlag, M.H., Jones, R.B., Kahn, J.B., Marrie, T.J., Ramirez, J.A., Saikku, P., Schachter, J., Schumacher, H.R., Stamm, W.E., Stratton, C.W., Yu, V.L. The importance of *Chlamydia pneumoniae* as a pathogen: The 1996 Consensus Conference on *Chlamydia pneumoniae* Infections. *Infect. Dis. Clin. Pract.* 6(Suppl 2):S28-S31, 1997.
56. Stratton, C.W.: Avoiding fluoroquinolone resistance: strategies for primary care practice. *Postgrad. Med.* 101:247-255, 1997.
57. Stratton, C.W.: An overview of plague: pathogenesis and clinical manifestations. *Antimicrobics Infect. Dis. Newsletter* 16:49-51, 1997.
58. Stratton, C.W.: Oxazolidinones: a new class of antimicrobial agents. *Antimicrobics Infect. Dis. Newsletter* 16:69-71, 1997.
59. Stratton, C.W., Coudron, P.E.: A practical approach to the diagnosis and therapy of *Helicobacter pylori* infection. *Antimicrobics Infect. Dis. Newsletter* 16: 81-86, 1997.



60. Stratton, C.W.: The immunopathology of chlamydial infections. *Antimicrobics Infect. Dis. Newsletter* 16:89-94, 1997.
61. Antony, S., Dummer, S., Stratton, C.W.: *Lactobacillus* bacteremia and endocarditis (Letter). *Clinical Infect. Dis.* 26:1483-1484, 1998.
62. Stratton, C.W.: Antibiotic resistance: strategies for counterattack. *Antimicrobics Infect. Dis. Newsletter* 17:1-6, 1998.
63. Stratton, C.W.: The role of *Chlamydia* in connective tissue diseases. *Antimicrobics Infect. Dis. Newsletter* 17:9-15, 1998.
64. Stratton, C.W.: The safety profile of fluoroquinolones. *Antimicrobics Infect. Dis. Newsletter* 17:57-60, 1998.
65. Stratton, C.W.: Catheter-associated infections: a necessary evil. *Antimicrobics Infect. Dis. Newsletter* 17:49-54, 1998.
66. Stratton, C.W.: Macrolides, lincosamides, and streptogramins: new agents and new roles. *Antimicrobics Infect. Dis. Newsletter* 17:89-95, 1998.
67. Stratton, C.W., Mitchell, W.M., Sriram, S.: Does *Chlamydia pneumoniae* play a role in the pathogenesis of multiple sclerosis? (Editorial) *J. Med. Microbiol.* 49:1-3, 2000.
68. Stratton, C.W.: Utilization of blood cultures in the 21<sup>st</sup> Century. *Antimicrobics Infect. Dis. Newsletter* 18:9-13, 2000.
69. Stratton, C.W.: Strongyloidiasis. *Antimicrobics Infect. Dis. Newsletter* 18:20-23, 2000.
70. Stratton, C.W.: Quinupristin/dalfopristin: the first parenteral streptogramin. *Antimicrobics Infect. Dis. Newsletter* 18:41-44, 2000.
71. Stratton, C.W.: Association of *Chlamydia pneumoniae* with chronic human diseases. *Antimicrobics Infect. Dis. Newsletter* 18:49-56, 2000.
72. Stratton, C.W.: Occupationally acquired infections: a timely reminder. (Editorial) *Infection Control Hosp. Epidemiol.* 22:8-9, 2001.
73. Stratton, C.W.: Get a handle on resistance before it gets a handle on you: the PROTEKT US Surveillance Study. *South Med J* 94:891-892, 2001.
74. Stratton, C.W.: Introduction: PROTEKT against respiratory tract infection. *J. Chemother.* 14(Suppl.):S5-S8, 2002.
75. Stratton, C.W.: Chloramphenicol. *Antimicrobics Infect. Dis. Newsletter* 18:89-91, 2002.

76. Stratton, C.W., Sriram S.: Association of *Chlamydia pneumoniae* with central nervous system disease. *Microbes Infect.* 13:1249-1253, 2003.
77. Sriram, S., Moses, H., Stratton, C.: CNS infection with *Chlamydia pneumoniae* complicated by multiple strokes. (Letter to the Editor) *J. Neurol.* 250:1127, 2003.
78. Tang, Y.W., Meng, S., Li, H., Stratton, C.W., Koyamatsu, T., Zheng, X.: PCR enhances acid-fast bacillus stain-based rapid detection of *Mycobacterium tuberculosis*. (Letter to the Editor) *J. Clin. Microbiol.* 42:1849-1850, 2004.
79. Mitchell, W.M., Stratton, C.W.: *Chlamydia pneumoniae* and acute coronary syndrome. (Letter to the Editor) *New England J. Med.* 353:525, 2005.

## CHAPTERS

1. Stratton, C.W.: Psittacosis. *In: Current Therapy.* Conn, H.F. (Ed.), W.B. Saunders Company, Philadelphia, 1978.
2. Hawley, H.B., Stratton, C.W., Horsman, T.A.: A selected field report on antibiotic review: role of infectious disease specialists in antibiotic usage. *In: Practical Aspects of Antibiotic Review*, pp. 301-305. Kunin, C.M. (Ed.), American Health Consultants, Atlanta, Georgia, 1979.
3. Stratton, C.W.: Susceptibility testing revisited. *In: Progress in Clinical Pathology, Volume IX*, pages 65-100. Stefanini, M., Gorstein, F., Fink, L.M. (Eds.), Grune and Stratton, Inc., Orlando, 1983.
4. Stratton, C.W.: The role of the microbiology laboratory in guiding formulary decisions: evaluating the significance of antimicrobial sensitivity data. *In: The Cost Conscious Antibiotic Formulary: An Idea Book for Hospital and Physicians*, pp. 39-46. McCue, J.D. (Ed.), Raven Press, New York, 1987.
5. Stratton, C.W.: Microbiologic evaluation of patients with skeletal infections. *In: Orthopedic Infections*, pp. 309-320. Marier, R.L., D'Ambrosia, R.D. (Eds.), Charles B. Slack, Inc., New Jersey, 1989.
6. Stratton, C.W.: Monitoring antibiotic blood levels in patients with skeletal infections. *In: Orthopedic Infections*, pp. 361-368. Marier, R.L., D'Ambrosia, R.D. (Eds.), Charles B. Slack, Inc., New Jersey, 1989.
7. Stratton, C.W., Tausk, F.: Intrinsic resistance of *Pseudomonas aeruginosa*. *In: Pseudomonas aeruginosa Infection*, pp. 275-286. Høiby, N., Pedersen, S.S., Shand, G.H., Doring, G., Holder, I.A. (Eds.), Antibiotics and Chemotherapy, Basel, Karger, 1989.

8. Stratton, C.W., Cooksey, R.C.: Susceptibility tests: special tests. *In: Manual of Clinical Microbiology*, Fifth Edition, pp. 1153-1165. Lennette, E.H., Balows, A., Hausler, Jr., W.J., Shadomy, H.J. (Eds.), American Society for Microbiology, Washington, D.C., 1991.
9. Stratton, C.W.: *In vitro* testing: correlations between bacterial susceptibility, body fluid levels and effectiveness of antibacterial therapy. *In: Antibiotics in Laboratory Medicine*, pp. 849-879. Third Edition. Lorian, V. (Ed.), The Williams & Wilkins Company, Baltimore, MD, 1991.
10. Stratton, C.W.: Rocky Mountain Spotted Fever. *In: Current Therapy*, pp. 128-131. 1993 Edition. Rakel, R.E. (Ed.), W.B. Saunders Company, Philadelphia, PA, 1993.
11. Stratton, C.W.: Attributes of infectious agents. *In: Infectious Diseases*, Fifth Edition. Chapter 1, pp. 2-19, Hoeprich, P.D., Jordan, M.C., Ronald, A.R. (Eds.), J.B. Lippincott Company, Philadelphia, PA, 1994.
12. Stratton, C.W.: *Streptococcus intermedius* group. *In: Principles and Practice of Infectious Diseases*, Fourth Edition. Chapter 182, pp. 1861-1865, Mandell, G.L., Bennett, J.E., Dolin, R. (Eds.), Churchill Livingstone, Inc., New York, NY, 1995.
13. Stratton, C.W.: Mechanisms of action for antimicrobial agents: General principles and mechanisms for selected classes of antibiotics. Chapter 13, pp. 579-603. *In: Antibiotics in Laboratory Medicine*, Fourth Edition. Lorian, V. (Ed.), The Williams & Wilkins Company, Baltimore, MD, 1996.
14. Greene, J., Stratton, C.W.: Role of the microbiology laboratory in hospital epidemiology and infection control. *In: Hospital Epidemiology and Infection Control*, Chapter 86, pp. 1126-1137. Mayhall, C.G. (Ed.), The Williams & Wilkins Company, Baltimore, MD, 1996.
15. Stratton, C.W., Decker, M.: Occupationally-acquired infections in post-hospital health-care workers. *In: Hospital Epidemiology and Infection Control*, Chapter 68, pp. 896-913. Mayhall, C.G. (Ed.), The Williams & Wilkins Company, Baltimore, MD, 1996.
16. Stratton, C.W.: Non-antibiotic effects of macrolide antibiotics: macrolide suppression of the bacterial glycocalyx of *Pseudomonas aeruginosa* isolates from cystic fibrosis patients. pp. 91-100. *In: Expanding Indications for the New Macrolides*. Zinner, Young, Acar, (Eds.), Marcel Dekker, Inc., New York, NY, 1997.
17. Midha, N.K., Stratton, C.W.: Laboratory tests for infectious diseases in the critical care setting. *In: Infectious Diseases in Critical Care Medicine*. Chapter 7, pp. 119-141. Cunha B.A. (Ed.) Marcel Dekker, Inc, New York, NY, 1998.
18. Antony, S.J., Stratton, C.W.: *Streptococcus intermedius* group. *In: Principles and Practice of Infectious Diseases*, Fifth Edition, pp 2183-2189. Mandell, G.L., Bennett, J.E., Dolin, R. (Eds.), Churchill Livingstone, Inc., New York, NY, 1999.

19. Antony, S.J., Stratton, C.W., Decker, M.: Prevention of occupationally acquired infections in posthospital healthcare workers. *In: Hospital Epidemiology and Infection Control*, Second Edition, Chapter 94, pp 1141-1158. Mayhall, C.G. (Ed.), The Williams & Wilkins Company, Baltimore, MD, 1999.
20. Stratton, C.W., Greene, J.: Role of the microbiology laboratory in hospital epidemiology and infection control. *In: Hospital Epidemiology and Infection Control*, Second Edition, Chapter 76, pp 1423-1435. Mayhall, C.G. (Ed.), The Williams & Wilkins Company, Baltimore, MD, 1999.
21. Stratton, C.W., Sriram, S., Yao, S., Tharp, A., Ding, L., Bannan, J.D., Mitchell, W.M.: Association of *Chlamydia pneumoniae* with multiple sclerosis: protocol for detection of *C. pneumoniae* in the CSF and summary of preliminary results. *In: Chlamydia pneumoniae and Chronic Diseases*, pp 137-141. L'age-Stehr, J. (Ed.), Springer, Berlin, 2000.
22. Sriram, S., Stratton, C.W., Yao, S., Bannan, J.D., Mitchell, W.M.: Association of multiple sclerosis with *Chlamydia pneumoniae*: demonstration of the 16S rRNA gene and immunoreactivity of CSF cationic antibodies against *C. pneumoniae* antigens. *In: Genes and Viruses in Multiple Sclerosis*, Chapter 25, pp 221-229. Hommes, O.R., Clanet, M., Wekerle, H. (Eds), Elsevier Science, Inc., New York, NY, 2001.
23. Stratton, C.W.: Occupationally-acquired infections in post-hospital health-care workers. *In: Hospital Epidemiology and Infection Control*, Third Edition, Chapter 84, pp 1449-1469. Mayhall, C.G. (Ed.), The Williams & Wilkins Company, Baltimore, MD, 2004.
24. Stratton, C.W., Greene, J.: Role of the microbiology laboratory in hospital epidemiology and infection control. *In: Hospital Epidemiology and Infection Control*, Third Edition, Chapter 101, 1809-1825. Mayhall, C.G. (Ed.), The Williams & Wilkins Company, Baltimore, MD, 2004.
25. Mirzanejad, Y., Stratton, C.W.: *Streptococcus intermedius* group. *In: Principles and Practice of Infectious Diseases*, Sixth Edition, Chapter 201, pp 2451-2457. Mandell, G.L., Bennett, J.E., Dolin, R. (Eds.), Churchill Livingstone, Inc., New York, NY, 2004.
26. Stratton, C.W.: Molecular mechanisms of action for antimicrobial agents: General principles and mechanisms for selected classes of antibiotics. *In: Antibiotics in Laboratory Medicine*, Fifth Edition, Chapter 12, pp 532-563. Lorian, V. (Ed.), The Williams & Wilkins Company, Baltimore, MD, 2005.
27. Qi, C., Stratton, C.W., Zheng, X. Phenotypic testing of bacterial antimicrobial susceptibility. *In: Advanced Techniques in Diagnostic Microbiology*, Chapter 5, pp 63-83. Tang, Y.W., Stratton, C.W. (Eds.), Springer, New York, NY, 2006.

## **UNITED STATES PATENTS**

1. Stratton, C.W., Mitchell, W.M.: Methods for *in vitro* susceptibility testing of *Chlamydia*. Patent Number: US 6,258,532 B1. Issued July 10, 2001.

2. Mitchell, W.M., *Stratton, C.W.*: Identification of antigenic peptide sequences.  
Patent Number: US 6,340,463 B1. Issued January 22, 2002.
3. Mitchell, W.M., *Stratton, C.W.*: *Chlamydia*-free cell lines and animals.  
Patent Number: US 6,562,582 B2. Issued May 13, 2003.
4. Mitchell, W.M., *Stratton, C.W.*: Diagnosis and management of infection caused by *Chlamydia*.  
Patent Number: US 6,579,854 B1. Issued June 17, 2003.
5. Mitchell, W.M., *Stratton, C.W.*: Diagnosis and management of infection caused by *Chlamydia*. Patent Number: US 6,664,239 B2. Issued December 16, 2003.
6. *Stratton, C.W.*, Mitchell, W.M., Sriram, S.: Methods and reagents for the treatment of multiple sclerosis.  
Patent Number: US 6,710,033 B1. Issued March 23, 2004.
7. Mitchell, W.M., *Stratton, C.W.*: Diagnosis and management of infection caused by *Chlamydia*.  
Patent Number US 6,756,369 B2. Issued June 29, 2004.
8. Mitchell, W.M., *Stratton, C.W.*: Diagnosis and management of infection caused by *Chlamydia*.  
Patent Number US 6,838,552 B2. Issued January 4, 2005.
9. Mitchell, W.M., *Stratton, C.W.*: Diagnosis and management of infection caused by *Chlamydia*.  
Patent Number US 6,884,784 B2. Issued April 26, 2005.
10. *Stratton, C.W.*, Mitchell, W.M., Sriram, S.: Methods and reagents for the treatment of multiple sclerosis.  
Patent Number: US 6,890,526 B1. Issued May 10, 2005.

### ***ABSTRACTS (National and International Meetings)***

1. *Stratton, C.W.*, Weeks, D.B., Reller, L.B.: Comparability of serum, broth and agar dilution methods. Presented at the 15th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, D.C., 1975.
2. *Stratton, C.W.*, Tenney, J.H., Reller, L.B.: Correlation of serum dilution tests with antimicrobial levels, MICs, and minimal lethal concentrations, and clinical outcome. Presented at the 16th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, 1976.

3. Tenney, J.H., Reller, L.B., *Stratton, C.W.*, Wang, W.L.: Controlled evaluation of volume of blood cultured and atmosphere incubation in detection of bacteremia. Presented at the 16th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, 1976.
4. Iannini, P.B., Weinstein, M.P., *Stratton, C.W.*, Eickhoff, T.C.: Spontaneous bacterial peritonitis in cirrhotics. Presented at the 16th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, 1976.
5. Hawley, H.B., *Stratton, C.W.*, Horsman, T.A.: Influence of infectious disease specialists on antimicrobial usage. Abstracts of the XII International Congress of Microbiology, September, Munich, Germany, 1976.
6. Tu, K.K., Jorgensen, J.M., *Stratton, C.W.*: A simple rapid accurate acidometric paper-disc method for detection of beta-lactamase production by bacteria. Presented at the 79th Annual Meeting of the American Society for Microbiology, Honolulu, Hawaii, 1979.
7. McKee, Jr., K., *Stratton, C.W.*, Cotton, R., Lavelly, G., Wright, P.F., Shenai, J., Melly, M., Farmer, J., Evans, M., Karzon, D., Schaffner, W.: Nursery outbreak of multiply-resistant *K. pneumoniae*: control and follow-up. Presented at the 20th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, Louisiana, 1980.
8. Evans, M.E., Schaffner, W., Federspiel, C.F., Cotton, R., McKee, Jr., K., Wright, P.F., *Stratton, C.W.*: Utility of surface cultures in a newborn intensive care unit. Presented at the 21st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, 1981.
9. *Stratton, C.W.*, Hawley, H.B., Evans, M.E., Horsman, T.A., Tu, K.K., Reller, L.B.: Reassessment of interpretive zone sizes for susceptibility testing of *Staphylococcal aureus*. Presented at the 21st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, 1981.
10. Evans, M.E., Patterson, L.S., *Stratton, C.W.*: Antimicrobial activity of clindamycin and U-57930E against *Staphylococcal aureus*. Presented at the 82nd Annual Meeting of the American Society for Microbiology, Atlanta, Georgia, 1982.
11. Aldridge, K.E., *Stratton, C.W.*, Patterson, L.S., Evans, M.E., Hodges, R.L.: Biotypes and antibiograms of coagulase-negative staphylococci isolated from blood and urine. Presented at the 82nd Annual Meeting of the American Society for Microbiology, Atlanta, Georgia, 1982.
12. Weinstein, M.P., *Stratton, C.W.*, Ackley, A.M., Hawley, H.B., Robinson, P.A., Fisher, B.D., Alcid, D.V., Reller, L.B.: Use of the serum bactericidal test to predict bacteriologic outcome in infective endocarditis. Presented at the 83rd Annual Meeting of the American Society for Microbiology, New Orleans, Louisiana, 1983.

13. Tausk, F., Evans, M.E., Patterson, L.S., *Stratton, C.W.*: N-Formimidoyl thienamycin-induced resistance of cephalosporins and penicillins in *Pseudomonas aeruginosa*. Presented at the 83rd Annual Meeting of the American Society for Microbiology, New Orleans, Louisiana, 1983.
14. *Stratton, C.W.*, Hawley, H.B., Patterson, L.S., Evans, M.E.: Inability of the standardized disk diffusion method to reliably determine the susceptibility of *Pseudomonas aeruginosa*. Presented at the 83rd Annual Meeting of the American Society for Microbiology, New Orleans, Louisiana, 1983.
15. Ratner, H.B., Tinsley, H., Keller, R.E., *Stratton, C.W.*: Comparison of refrigerated versus room temperature media on the recovery of *Neisseria gonorrhoeae* from genital specimens. Presented at the 84th Annual Meeting of the American Society for Microbiology, St. Louis, Missouri, 1984.
16. *Stratton, C.W.*, Judson, F.N., Simpson, E.B., Jones, M.R., Kasselberg, A.G.: Comparison of immunoperoxidase staining with iodine staining for the detection of *Chlamydia trachomatis* inclusion in McCoy Cells. Presented at the 84th Annual Meeting of the American Society for Microbiology, St. Louis, Missouri, 1984.
17. Tausk, F., Patterson, L.S., Evans, M.E., *Stratton, C.W.*: Increased minimal inhibitory concentration of antipseudomonal beta-lactam antibiotics against *Pseudomonas aeruginosa* caused by subinhibitory concentrations of N. formimidoyl thienamycin. Presented at the 84th Annual Meeting of the American Society for Microbiology, St. Louis, Missouri, 1984.
18. Tausk, F., *Stratton, C.W.*: Evidence for the involvement of beta-lactamase in the antagonism of both hydrolyzable and non-hydrolyzable beta-lactam antibiotics. Presented at the 24th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, D.C., 1984.
19. Ratner, H.B., *Stratton, C.W.*: Thermonuclease test for same day identification of *Staphylococcus aureus* from blood cultures. Presented at the 24th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, D.C., 1984.
20. Mitchell, W.M., Forti, R.L., Lawton, A.R., Vogler, L.B., *Stratton, C.W.*, Gregg, C.R.: Spontaneous and interferon resistant natural killer cell anergy in AIDS. J. Cell. Biochem. 8A:15, Abstract 0026. 1984.
21. Ratner, H.B., Weeks, L.S., *Stratton, C.W.*: Evaluation of the spot CAMP test for the identification of Group B streptococci. Presented at the 25th Interscience Conference on Antimicrobial Agents and Chemotherapy, Minneapolis, Minnesota, 1985.
22. Weinstein, M.P., Reller, L.B., Mirrett, S., *Stratton, C.W.*, Wang, W.L., Reimer, L.G.: Controlled evaluation of Septi-Chek and Bactec blood culture systems. Presented at the 85th Annual Meeting of the American Society for Microbiology, Las Vegas, Nevada, 1985.

23. Ratner, H.B., *Stratton, C.W.*: Clinical usefulness of the LN strip versus urine culture. Presented at the 85th Annual Meeting of the American Society for Microbiology, Las Vegas, Nevada, 1985.
24. Peters, T.H., Lefkowitz, L.B., Ratner, H.B., Davidson, T.L., *Stratton, C.W.*: Clinical evaluation of the MicroTrak direct specimen test for the detection of *Chlamydia trachomatis* in genital specimens. Presented at the 85th Annual Meeting of the American Society for Microbiology, Las Vegas, Nevada, 1985.
25. Evans, M.E., *Stratton, C.W.*, Reller, L.B.: Effect of medium on broth dilution susceptibility testing *Pseudomonas aeruginosa*. Presented at the 86th Annual Meeting of the American Society for Microbiology, Washington, D.C., 1986.
26. Tausk, F., *Stratton, C.W.*: Effect of clavulanic acid on the activity of ticarcillin against *Pseudomonas aeruginosa*. Presented at the 86th Annual Meeting of the American Society for Microbiology, Washington, D.C., 1986.
27. Lefkowitz, L.B., Peters, T.H., Ratner, H.B., Davidson, T.L., *Stratton, C.W.*: Chlamydia screening of male patients with gonorrhea. Presented at the 86th Annual Meeting of the American Society for Microbiology, Washington, D.C., 1986.
28. Aldridge, K.E., *Stratton, C.W.*, Weeks, L.P., Sanders, C.V.: Bactericidal activity of cefotaxime, cefoxitin, ceftizoxime, chloramphenicol, clindamycin, and metronidazole using kill-kinetic studies against *Bacteroides fragilis* group isolates. Presented at the XIth International Congress of Infectious and Parasitic Disease, Munich, Germany, 1986.
29. Aldridge, K.E., *Stratton, C.W.*, Weeks, L.P., Sanders, C.V.: Synergistic bactericidal activity of cefotaxime and desacetylcefotaxime in combination versus the antibiotics alone against strains of *Bacteroides fragilis* group. Presented at the XIth International Congress of Infectious and Parasitic Disease, Munich, Germany, 1986.
30. Aldridge, K.E., *Stratton, C.W.*, Sanders, C.V.: The role of desacetylcefotaxime in the potentiation of cefotaxime against *Bacteroides* species: comparison of *in vitro* versus *in vivo* studies. Presented at the XIth International Congress of Infectious and Parasitic Disease, Munich, Germany, 1986.
31. Weeks, L.S., Liu, C., *Stratton, C.W.*: Bactericidal activity of LY 146032 compared with methicillin, cefazolin, cefamandole, cefuroxime, ciprofloxacin, and vancomycin against staphylococci as determined by kill-kinetic studies. Presented at the 87th Annual Meeting of the American Society for Microbiology, Atlanta, Georgia, 1987.
32. Ratner, H.B., Liu, C., Weeks, L.S., *Stratton, C.W.*: Bactericidal activity of LY 146032 compared with ciprofloxacin, vancomycin, ampicillin, and gentamicin against enterococci as determined by kill-kinetic studies. Presented at the 87th Annual Meeting of the American Society for Microbiology, Atlanta, Georgia, 1987.



33. Stratton, C.W., Weinstein, M.P., Mirrett, S., Parsky, J., Laner, B.A., Reller, L.B.: Controlled evaluation of blood culture medium containing gelatin for the detection of septicemia in children. Presented at the 87th Annual Meeting of the American Society for Microbiology, Atlanta, Georgia, 1987.
34. Kernodle, D.S., Stratton, C.W., Williams, L., Kaiser, A.B.: Phenotypic subgroups of beta-lactamase producing *Staphylococcus aureus*: relationship to beta-lactamase immunotype. Presented at the 27th Interscience Conference on Antimicrobial Agents and Chemotherapy, New York City, New York, 1987.
35. Stratton, C.W., Aldridge, K.E.: Bactericidal activity of ticarcillin alone and in combination with clavulanic acid compared to those of cefoxitin, clindamycin, and metronidazole using kill-kinetic studies with *Bacteroides fragilis* group isolates. Presented at a symposium "Therapeutic Considerations in the Management of Infectious Disease: Today and Tomorrow," Montreux, Switzerland, 1987.
36. Kernodle, D.S., Stratton, C.W., McMurray, L.W., Chipley, J.R., McGraw, P.A.: Beta-lactamase variants of *Staphylococcus aureus*: differentiation by substrate profile and isoelectric focusing. Presented at the 28th Interscience Conference on Antimicrobial Agents and Chemotherapy, Los Angeles, CA, 1988.
37. McMurry, L., Barg, N., Kernodle, D., Stratton, C.: Characteristics of a widespread strain of methicillin-susceptible *S. aureus* from wound infections failing cephalosporin prophylaxis. Presented at the 28th Interscience Conference on Antimicrobial Agents and Chemotherapy, Los Angeles, CA, 1988.
38. Mirrett, S., Reller, L.B., Stratton, C.W.: Controlled comparison of low (5-ml) and high (10-ml) blood volumes in BACTEC aerobic and anaerobic media. Presented at the 88th Annual Meeting of the American Society for Microbiology, Miami Beach, FL, 1988.
39. Ratner, H.B., Stratton, C.W.: Identification of mucoid lactose fermenters from urine cultures: a cost-effective procedure. Presented at the American Society for Microbiology Annual Meeting, Miami Beach, FL, 1988.
40. Stratton, C.W.: Bactericidal activity of NY198 and ciprofloxacin against selected pathogens. Presented at the VI Mediterranean Congress of Chemotherapy, Taromina, Italy, 1988.
41. Aldridge, K.E., Stratton, C.W.: Studies of the inhibitory and bactericidal activity of ceftizoxime, cefoxitin, and cefotetan against strains of *Bacteroides fragilis* group: comparison of time-kill kinetic studies to MIC values. Presented at the VI Mediterranean Congress of Chemotherapy, Taromina, Italy, 1988.
42. Zygmunt, D.J., Kernodle, D.S., Stratton, C.W., McGraw, P.A.: Beta-lactamases produced by *S. epidermidis*: characterization of two commonly recovered variants. Presented at the 89th Annual Meeting of the American Society for Microbiology, New Orleans, LA, 1989.

43. Zygmunt, D.J., Stratton, C.W., Kaiser, A.B., Kernodle, D.S.: Comparison of beta-lactamases produced by *S. epidermidis* and *S. aureus*. Presented at the 29th Interscience Conference on Antimicrobial Agents and Chemotherapy, Houston, TX, 1989.
44. Stratton, C.W., Aldridge, K.E.: Comparative bactericidal activity of selected antimicrobial agents against cefoxitin-sensitive and cefoxitin-resistant *Bacteroides fragilis* group isolates. Presented at the Third European Congress on Anaerobic Bacteria and Infections, Munich, Germany, 1989.
45. Stratton, C.W.: Evaluation of the effect (indifferent, additive, synergistic, or antagonistic) of lomefloxacin on the bactericidal activity of metronidazole against selected anaerobic bacteria as determined by time-kill kinetic methodology. Presented at the 16th International Congress of Chemotherapy Annual Meeting, Jerusalem, Israel, 1989.
46. Norris, S.R., Stratton, C.W., Kernodle, D.S.: Beta-lactamases produced by methicillin-resistant strains of *Staphylococcus aureus*. Presented at the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlanta, GA, 1990.
47. Aldridge, K.E., Weeks, L., Stratton, C.W.: Bactericidal activity of ceftizoxime, cefotetan, and clindamycin against cefoxitin-resistant *B. fragilis* group isolates. Presented at the 90th Annual Meeting of the American Society for Microbiology, Anaheim, CA, 1990.
48. Weinstein, M.P., Mirrett, S., Wilson, M., Harrell, L., Stratton, C.W., Reller, L.B.: Controlled evaluation of the BACTEC PLUS 26 and Roche Septi-Chek aerobic blood culture bottles. Presented at the 90th Annual Meeting of the American Society for Microbiology, Anaheim, CA, 1990.
49. Wilson, M.L., Harrell, L.J., Mirrett, S., Weinstein, M.P., Stratton, C.W., Reller, L.B.: Controlled comparison of BACTEC PLUS 27 and Roche Septi-Chek anaerobic blood culture bottles. Presented at the 90th Annual Meeting of the American Society for Microbiology, Anaheim, CA, 1990.
50. Stratton, C.W., Schaffner, W.: Focused microbiological surveillance by specific hospital unit as a more sensitive means of defining bacterial resistance problems. Presented at the 3rd International Conference on Nosocomial Infections, Atlanta, GA, 1990.
51. Aldridge, K.E., Weeks, L., Stratton, C.W.: Beta-lactam/beta-lactamase inhibitor combinations against *Bacteroides fragilis* group: potential of inhibitory and bactericidal activity. Presented at the 17th International Congress of Chemotherapy, Berlin, Germany, 1991.
52. Pappas, P.G., Pottage, J.C., Tapper, M.L., Shafer, R.W., Blum, R.N., Bonebrake, F.C., Klein, B., Chmel, H., Stratton, C.W., Powderly, W.G., Dismukes, W.E.: Blastomycosis in AIDS Patients. Presented at the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlanta, GA, 1991.

53. Macon, W.R., Lo, S-C., Poiesz, B.J., Montefiori, D.C., Mason, T.E., Michael, P.R., Cohen, A.G., Davis, C.M., Cousar, J.B., *Stratton, C.W.*: AIDS-like illness associated with systemic *Mycoplasma fermentans* infection in an HIV-negative. Presented at the Annual Meeting of the United States and Canadian Academy of Pathology, New Orleans, LA, 1992.
54. Cherubin, C., *Stratton, C.W.*: Bactericidal activity of fluoroquinolones against *Listeria monocytogenes*. Presented at the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, CA, 1992.
55. Coudron, P., Kirby, D., *Stratton, C.W.*: Evaluation of time-kill methods for bismuth and ampicillin against *Helicobacter pylori*. Presented at the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, CA, 1992.
56. Ferraro, M.J., Braidt, J., Murtaugh, P., *Stratton, C.W.*, Ratner, H., Schreckenberger, P., Ristow, K., Snyder, J., Lude, S., Eisenach, K., Lewno, M.J., Wakefield, T., Antik, N., Filburn, B., Charache, P.: Evaluation of the NR-860 blood culture system. Presented at the 92nd Annual Meeting of the American Society for Microbiology, New Orleans, LA, 1992.
57. *Stratton, C.W.*: Susceptibilities of cephamycin-resistant strains of the *Bacteroides fragilis* group to newer antimicrobial agents. Presented at the Fourth European Congress & Second International Symposium on Anaerobic Bacteria and Infections, Vienna, Austria, 1992.
58. Cherubin, C.E., *Stratton, C.W.*: The bactericidal activity of sparfloxacin, ofloxacin, ciprofloxacin, and other fluoroquinolones against *Listeria monocytogenes*. Presented at the 4th International Symposium on New Quinolones, Munich, Germany, 1992.
59. Cherubin, C.E., *Stratton, C.W.*: *In vitro* activity of biapenem versus ceftazidime-resistant strains of *Klebsiella pneumoniae* and *Escherichia coli*. Presented at the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, 1993.
60. *Stratton, C.W.*, Kernodle, D.S., Kaiser, A.B.: Enhanced rates of killing *in-vitro* and *in vivo* due to synergy at the penicillin-binding protein level by the combination of ampicillin and sulbactam against a beta-lactamase-negative strain of *Staphylococcus aureus*. Presented at the 18th International Congress of Chemotherapy, Stockholm, Sweden, 1993.
61. *Stratton, C.W.*, Aldridge, K.E.: Bactericidal activity of beta-lactamase inhibitor combinations against cephamycin-resistant strains of the *Bacteroides fragilis* group. Presented at the 6th European Congress of Clinical Microbiology and Infectious Diseases, Seville, Spain, 1993.
62. *Stratton, C.W.*, Ratner, H., Johnston, P.E., Schaffner, W.: Focused microbiologic surveillance by specific hospital unit: practical application and clinical utility. Presented at the 6th European Congress of Clinical Microbiology and Infectious Diseases, Seville, Spain, 1993.

63. Brandt, C.M., Rouse, M.S., Tallan, B.M., Laue, N.W., Stratton, C.W., Wilson, W.R., Steckelberg, J.M.: Effective treatment of multi-drug resistant enterococcal experimental endocarditis with combinations of cell-wall active agents. Presented at the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, FL, 1994.
64. Haas, D.W., Stratton, C.W., Griffin, J.P., Weeks, L., Allis, S.C.: Decreased activity of ceftizoxime against penicillin-resistant *Streptococcus pneumoniae*: A call for formulary caution during cost-conscious times. Presented at the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, FL, 1994.
65. Skov, R., Williams, T.J., Espersen, F., Rosdahl, V.T., Stratton, C.W., Kernodle, D.S.: An increased prevalence of nosocomial infections caused by *Staphylococcus aureus* phage-group II with plasmid-mediated type C beta-lactamase production. Presented at the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, FL, 1994.
66. Yee, Y.C., Harley, H.W., Stratton, C.W.: Characterization of *Pseudomonas aeruginosa* PA50 beta-lactamase. Presented at the 94th Annual Meeting of the American Society for Microbiology, Las Vegas, CA, 1994.
67. Hyatt, J.M., Nix, D.E., Stratton, C.W., Schentag, J.J.: *In-vitro* pharmacodynamics of piperacillin, ciprofloxacin, and piperacillin-tazobactam in single agent and combination studies. Presented at the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, FL, 1994.
68. Stratton, C.W.: Comparison of killing kinetics for selected fluoroquinolones versus cell-wall active agents against penicillin-susceptible and -resistant isolates of *Streptococcus pneumoniae*. Presented at the 5th International Symposium on New Quinolones, Singapore, 1994.
69. Stratton, C.W.: Surveillance of *Pseudomonas aeruginosa* susceptibility in five tertiary care hospitals. Presented at the 5th International Symposium on New Quinolones, Singapore, 1994.
70. Hyatt, J.M., Nix, D.E., Stratton, C.W., Schentag, J.J.: Relative potential for five classes of antimicrobial agents, alone and in combination, to select/induce oxacillin resistance in susceptible *Staphylococcus aureus*. Presented at the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1995.
71. Stratton, C.W., Aldridge, K.E.: High-level resistance to clindamycin (MIC > 256 mcg/ml) in cefoxitin-resistant members of the *Bacteroides fragilis* group is associated with a relative decrease in the activities of metronidazole, chloramphenicol, and beta-lactam/beta-lactamase inhibitor combinations. Presented at the World Congress on Anaerobic Bacteria and Infections, San Juan, Puerto Rico, 1995.
72. Ainsworth, S., Gelfand, M., Stratton, C.W.: *In-vitro* assessment of ciprofloxacin in combination with an antipseudomonal beta-lactam agent versus *Pseudomonas aeruginosa*. Presented at the 7th European Conference of Clinical Microbiology and Infectious Diseases, Vienna, Austria, 1995.

73. Mirzanejad, Y., Kernodle, D.S., Stratton, C.W.: Rapid killing of *Mycobacterium tuberculosis* Strain H37R<sub>a</sub> by beta-lactam antibiotics. Presented at the International Symposium in *Mycobacterium tuberculosis* Biannual Meeting, Washington, DC, 1996.
74. Mirzanejad, Y., Kernodle, D.S., Stratton, C. W.: Susceptibility testing for mycobacteria. Presented at the 36th Interscientific Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, 1996.
75. Stratton, C.W.: Non-antibiotic effects of macrolide antibiotics: macrolide suppression of the bacterial glycocalyx of *Pseudomonas aeruginosa* isolates from cystic fibrosis patients. Presented at the Third International Conference on Macrolides, Azalides, and Streptogramins, Lisbon, Portugal, 1996.
76. Antony, S.J., Dummer, J.S., Stratton, C.W.: Combination of cell-wall active agents for high-level aminoglycoside resistant *Enterococcus faecalis* causing endocarditis. Presented at the 35th Annual Meeting of the Infectious Diseases Society of America, San Francisco, CA, 1997.
77. Miller, S.D., Fang, G.D., Stratton, C.W., Scheld, W.N.: Combination of ceftriaxone and ampicillin: a successful therapy in an experimental penicillin-resistant *Streptococcus pneumoniae* (PRSP) meningitis model. Presented at the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 1998.
78. Sriram, S., Yao, S.-Y., Stratton, C.W., Mitchell, W.M.: *Chlamydia pneumoniae* infection of the CNS in patients with relapsing remitting MS. Abstract S78.002. Presented at the Annual Meeting of the American Academy of Neurology, Toronto, Canada, 1999.
79. King, L.E., Jr., Stratton, C.W., Mitchell, W.M.: *Chlamydia pneumoniae* and chronic skin infections. Presented at the Montagne Symposium on Emerging Pathogens, Snowmass, CO, 2000.
80. Alberts, G.L., Stratton, C.W., Mitchell, W.M., Franke, J.J.: Potential role of *Chlamydia pneumoniae* in the pathogenesis of interstitial cystitis. Abstract presented at the Annual Meeting for the Society for Urodynamics and Female Urology, Anaheim, CA, 2001.
81. Stratton, C.W., Barry, A., Yee, Y.C.: *In Vitro* Activity of telithromycin against clinical isolates of *Streptococcus pneumoniae* collected from 214 medical centers across the United States during the winter of 2000/2001. Poster Presentation. Presented at the 41<sup>st</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2001.
82. Stratton, C.W., Brown, S.: Increasing macrolide resistance among community-acquired bacterial pathogens from lower respiratory tract infections across the USA. Poster Presentation. Presented at the 98<sup>th</sup> International Conference of the American Thoracic Society, Atlanta, GA, 2002.

83. Stratton, C.W., Brown, S.: The ketolide telithromycin shows potent activity against common bacterial pathogens isolated from patients with community-acquired respiratory tract infections (CARTI). Poster Presentation. Presented at the 98<sup>th</sup> International Conference of the American Thoracic Society, Atlanta, GA, 2002.
84. Stratton, C.W., Brown, S., Yee, Y.C.: Telithromycin, a novel ketolide antibacterial, is highly active against *Streptococcus pneumoniae* isolates collected from across the USA during 2000-2001, irrespective of the presence of penicillin G, macrolide or fluoroquinolone resistance. Poster Presentation. Presented at the 102<sup>nd</sup> General Meeting of the American Society for Microbiology, Salt Lake City, UT, 2002.
85. Pennella, T.D., Tang, Y., Stratton, C.W., McKenna, T., Bannan, JD. Nosocomial strain relationships assessed by genotyping and MALDI-TOF mass spectrometry. Poster Presentation. Presented at the 42<sup>nd</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 2002.
86. Stratton, C.W., Midha, N.: *In vitro* activity of telithromycin against *Streptococcus pneumoniae* (SPN) resistant to penicillin, macrolides and/or levofloxacin isolated in the USA (2000-01). Poster Presentation. Presented at the 99<sup>th</sup> International Conference of the American Thoracic Society, Seattle, WA, 2003.
87. Tang, Y. W., Sriram, S., Li, H. J., Yao, Y. S., Meng, S., Mitchell, W. M., Stratton, C. W.: Qualitative and quantitative detection of *Chlamydia pneumoniae* DNA in cerebrospinal fluid. Poster Presentation. Presented at the 13<sup>th</sup> European Conference on Clinical Microbiology and Infectious Diseases, Glasgow, UK, 2003.
88. Tang, Y. W., Meng, S., Li, H., Koyamatsu, T., Stratton, C. W., and Zheng, X.: A colorimetric microtiter plate PCR detects *Mycobacterium tuberculosis* in NALC-NaOH-decontaminated respiratory specimens. Poster Presentation. Presented at the 103<sup>rd</sup> General Meeting of the American Society for Microbiology, Washington, DC, 2003.
89. Sriram, S., Song, Y., Moses, H., Stratton, C.W., Wolinsky J.: A pilot study to examine the effect of antibiotic therapy on MRI outcomes in relapsing remitting MS. Poster Presentation. Presented at the Annual Meeting of the American Academy of Neurology, San Francisco, CA, 2004.
90. Tang, Y.W., Li, H.J., Durkin, M., Sefers, S.E., Meng, F., Connolly, P., Stratton, C.W., Wheat, L.J. Detection of *Histoplasma capsulatum* in urine by PCR and its role in the diagnosis of histoplasmosis. Poster Presentation. Presented at the 105<sup>th</sup> General Meeting of the American Society for Microbiology, Atlanta, GA, 2005.
91. Muldrew, K.L., Simpson, J.F., Stratton, C.W., Tang, Y. Molecular diagnosis of “flesh eating bacteria”. Poster Presentation. Presented at the 105<sup>th</sup> General Meeting of the American Society for Microbiology, Atlanta, GA, 2005.

92. Sefers, S.E., Webster-Clair, D.C., *Stratton, C.W.*, Tang, Y.W. Detection of *Chlamydia trachomatis* and *Neisseria gonorrhoeae* from endocervical swabs: a comparative evaluation of three commercial kits. Poster Presentation. Presented at the 105<sup>th</sup> General Meeting of the American Society for Microbiology, Atlanta, GA, 2005.

93. Rankin, J.S., Johnson, D.C., Glower, D.D., Teichmann, T.L., Muhlbaier, L.H., *Stratton, C.W.* Immune augmentation for pulmonary infection after valve surgery. Poster Presentation. Presented at the 8<sup>th</sup> International Symposium on Modern Concepts in Endocarditis and Cardiovascular Infections, Charleston, SC, 2005.

94. Antony, S., *Stratton, C.W.* Clinical experience with daptomycin in patients with orthopedic-related infections. Poster Presentation. Presented at the 43<sup>rd</sup> Annual Meeting of the Infectious Diseases Society of America, San Francisco, CA, 2005.